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Abstract 
The transcription factor NF-κB can play both a protective and destructive role in cells. NF-κB 
protects by signalling for the immune system when cells fall under attack from pathogens. 
NF-κB signalling becomes a danger to cells when signalling becomes constitutive and can 
promote excessive inflammation and tumourigenesis. Constitutive NF-κB signalling occurs 
within acute myeloid leukaemia cells, promoting cell survival. This provides reason to 
investigate the NF-κB signalling pathway in greater detail. Prevention of NF-κB signalling 
should lead to cell apoptosis of AML cells but this outcome may be affected by any one of 
the many signalling components that make up the extremely complex NF-κB signalling 
pathway. A range of the NF-κB signalling components within AML cells are investigated in 
detail this study.  It was uncovered that although p50 NF-κB levels were consistent in AML 
and control cell samples, IκB levels were markedly reduced, leading to greater basal NF-κB 
activity in AML cancer cells compared to control non-cancer cells.  Furthermore, this 
inhibited IκB level observed in AML cells, appeared to be maintained by autocrine TNF 
production, as anti-TNF treatment impaired the observed response.  These findings indicate 
that IκB levels underlie the high basal NF-κB activity that is observed in AML cancer cells, 
and possibly other types of NF-κB-dependent cancers.  Targetting IκB may help improve 
cancer chemotherapeutic effectiveness in AML.  
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This study investigates one particular type of cancerous disease: acute myeloid leukaemia. It 
is a potentially lethal cancer affecting the white blood cells, whose cellular signalling 
becomes disrupted, leading to their aberrant proliferation and growth. The NF-κB signalling 
pathway plays a major role in regulating such activities within a cell therefore components of 
the pathway are studied in a degree of detail to provide an insight into their roles in AML.  
 
1.1 Cancer 
Many human tissues undergo rapid and continuous cell turnover to maintain their normal 
and healthy physiology. For example in colonic mucosa or in the peripheral blood the life 
span of a mature, differentiated cell can be measured in days or even hours (Dalerba et al 
2006). Human tissues maintain this continuous cell turnover through a tightly regulated 
process of renovation sustained by a small amount of long-lived stem cells with 
extraordinary expansion potential.  
 
Cancer occurs when this process of cell turnover becomes aberrant. This can occur as a 
result of both internal factors (such as inherited mutations, hormones, and immune 
conditions) and environmental/acquired factors (such as tobacco, diet, radiation, and 
infectious organisms (Anand et al 2008). These environmental factors can cause or enhance 
abnormalities in the genetic material of cells (Kinzler et al 2002). The mutations found in the 
cancer cell genome accumulate over the lifetime of the cancer patient (Aggarwal et al 2011). 
If mutations occur in oncogenes or tumour suppressor genes, the tight regulation of cell 
turnover is lost, therefore causing cells to proliferate abarrently and form a mass which is 
known as a tumour. Nuclear factor-kappaB (NF-κB) is a transcription factor which has an 
established critical role in cancer (Chaturvedi et al 2011). It has both tumour suppressor and 
oncogenic properties, either of which can lead to tumourigenesis. 
  
Tumours where the cancerous cells remain clustered together in a single mass are known 
as benign (Alberts et al 2002). Cancerous cells may gain the ability to break loose from a 
tumour and invade surrounding tissue. This is a property of malignant tumours. Malignant 
tumours may enter the bloodstream or lymphatic vessels and form secondary tumours called 
metastases at other sites within the body (Alberts et al 2002).  
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Cancers are classified according to the tissue and cell type from which they arise. Cancers 
that arise from epithelial cells are called carcinomas; those arising from connective tissue or 
muscle cells are called sarcomas; and cancers that do not fit into either of these two broad 
categories include cancers derived from cells of the nervous system, and leukaemias 
(Alberts et al 2002).  
 
1.2 Leukaemia  
1.2.1 Introduction 
This section will give an introduction into Leukaemia. It will initially introduce leukaemia as a 
disease in more general terms, then progress to provide more detail about the specifics of 
various types. The French-American-British and World Health Organisation systems of 
leukaemia classification are described and for each class there is a brief summary of their 
epidemiology, symptoms, immunology, causes, diagnosis and treatment.  
 
Leukaemia is a cancer of the blood and bone marrow that involves an increase in white 
blood cell count to a level that is above normal. Control mechanisms in the blood are 
disrupted causing the bone marrow to produce excess numbers of abnormal white blood 
cells that do not become mature, thus affecting their ability to function properly. 
Overproduction of white blood cells displaces the production of other blood cells and 
components which leads to the demise of normal properties and functions of the blood 
system. 
  
Leukaemia is a disease that varies greatly among patients. Therefore to aid communication 
between patients, medical professionals, researchers and the general public, leukaemia is 
divided clinically and pathologically into separate classes. Such classification is explored in 
the following section.  
 
1.2.2 Classification 
Leukaemia can be classified into being either lymphoid or myeloid, depending on which 
lineage of white blood cell is affected. Lymphoblastic or lymphocytic leukaemias can develop 
due to defects in lymphoid progenitor cells which would normally mature to form infection-
fighting lymphocytes of the immune system. B cells, T cells or natural killer (NK) cells can 
become affected. Myeloblastic or myelocytic leukaemias arise due to disorders in myeloid 
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progenitor cells which prevent proper maturation and differentiation into basophils, 
neutrophils, eosinophils and monocytes which are immature macrophages.  
Further classification reflects the speed of progression of the disease, either chronic or 
acute. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Intro Figure 1: The formation of blood cells of different lineages from a stem cell. 
[www.cancerhelp.org.uk]. 
 
 
Acute leukaemias progress rapidly due to the rapid accumulation of immature blood cells. 
These are the most common forms of leukaemia in children and require immediate 
treatment. Chronic leukaemias have an excessive build up of relatively mature, abnormal 
white blood cells but take months or years to progress. Eventually though, because the 
abnormal cells are produced at a much higher rate than normal cells, a high proportion of 
abnormal cells will accumulate in the blood. Chronic leukaemia treatment does not 
necessarily need to happen immediately as some chronic leukaemia treatment can be most 
effective if treatment follows a monitoring period first. Chronic leukaemia is more prevalent in 
the older population. Chronic leukaemias are a rare disease in childhood, around 98% of 
childhood leukaemias are acute (Cwynarski et al 2003).  
 
Such classification gives four main groups of disease: Acute Lymphoblastic Leukaemia 
(ALL), Acute Myeloid Leukaemia (AML), Chronic Lymphoblastic Leukaemia (CLL) and 
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Chronic Myeloid Leukaemia (CML). As previously defined, the different categories of 
leukaemia each have their own variations of cause, symptoms and groups of people who are 
most affected.  
 
1.2.2.1 Chronic leukaemias 
Chronic myelogenous leukaemias (CML)  
CMLs are defined by the WHO as myeloproliferative diseases that are characterised by the 
presence of the Philadelphia chromosome (Vardiman et al 2002). The Philadelphia 
chromosome results from a reciprocal translocation between chromosomes 9 and 22 which 
leads to the fusion of the BCR and ABL genes in haematopoietic progenitor cells. This in 
turn leads to production of chimeric proteins with increased tyrosine kinase activity. CML in 
children is characterised by the same molecular, cytogenetic and morphologic features that 
are observed in adults, with classical Philadelphia-positive (Ph+) CML (Grier et al 1992). 
CML is characterised by a biphasic or triphasic clinical course in which a benign chronic 
phase is followed by transformation into an accelerated and blastic phase, which is often 
fatal (Faderl et al 1999).  
 
CML is treated with chemotherapy reagents such as hydroxyurea or busulfan to maintain 
haematologic control; however these chemotherapeutic drugs cannot change the course of 
the disease (Faderl et al 1999). More recently, CML have received a standard treatment of 
imatinib which is an inhibitor of BCR-ABL tyrosine kinase. Also, interferon alpha (IFNα) is an 
alternative treatment in the early chronic phase for patients who do not tolerate imatinib 
(Hehlmann et al 2007). Depending on their age and donor availability, CML patients can be 
treated with allogenic stem cell transplantation if other treatment fails. Complete cytogenic 
remission is achieved by 87% of patients (Hehlmann et al 2007).  
 
Chronic lymphocytic leukaemia (CLL) 
CLL is the most common human leukaemia. It is a malignancy of mature B cells with 
rearranged immunoglobulin (Ig) genes (Rosenwald et al 2001) and characterised by the 
accumulation of monoclonal B cells with the appearance of small mature lymphocytes with a 
characteristic immunophenotype (Hamblin et al 1999). Such cells are typically positive for 
CD5, CD23 and CD19 however surface immunoglobulins (IgM and IgD) are sparse (Hamblin 
et al 1999). 
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Neoplastic cells in patients with CLL over express the proto-oncogene protein Bcl-2, 
providing them with resistance to apoptosis (Hamblin et al 1999). Proto-oncogene Bcl-2 can 
occur as a result of a chromosomal translocation between chromosomes 14 and 18 however 
T- and B-lymphoid cells have found to be present with the bcl-2 protein but without the 14;18 
chromosomal translocation (Pezzella et al 1990).  
 
It has been suggested by Rosenwald et al (2001) that CLL may be separated into two 
different diseases: one derived from an Ig-un-mutated pre-germinal centre B cell and 
theother derived from an Ig-mutated B cell that has passed through the germinal centre. This 
model of two CLL diseases has been further supported by findings that Ig-un-mutated and Ig 
mutated CLL patients have different clinical courses (Hamblin et al 1999). Resenwald et al 
investigated this two disease model and found that B cell activation genes were differentially 
expressed between the two Ig-mutational subgroups in CLL. This gave the possibility that 
more aggressive clinical behaviour of the Ig-un-mutated subtype is caused by signalling 
pathways downstream of the B cell receptor (BCR).  
 
1.2.2.2 Acute Leukaemias 
Acute Lymphoblastic Leukaemia (ALL) 
Acute leukaemias are classified into acute myeloid leukaemia subtypes (see below) and 
acute lymphocytic leukaemia (ALL).  ALL is a malignant disorder of lymphoid progenitor cells 
which affects both children and adults; however the peak prevalence is in children between 
the ages of two and five years. The cure rate for this particular disease is above 80% for 
children. Less than five percent of cases are associated with inherited or predisposing 
genetic syndromes, with ionising radiation or with exposure to specific chemotherapeutic 
drugs (Pui et al 2008). The exact pathogenetic events that occur in the development of ALL 
are unknown however it is thought to originate from genetic lesions in blood-progenitor cells 
that are committed to differentiate in the T-cell or B-cell pathway, which include mutations 
that provide cells with the capacity for unlimited self-renewal and mutations that cause 
stage-specific developmental arrest (Pui et al 2004). Cells become affected by ALL disease 
mutations in several ways: immunoglobulin or T-cell receptor genes have clonal 
rearrangements, antigen receptor molecules are expressed, and cell surface glycoproteins 
tend to resemble those of early developmental stage normal T and B lymphocytes.  
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Initial treatment of ALL consists of a combination of antibiotic drugs such as anthracyclines 
which provides a remission rate of up to 80% (National Cancer Institute 2010). If a patient 
experiences relapse, bone marrow transplantation may be considered (Bortin et al 1980). 
Treatment is generally more successful in younger patients which could be related to 
increased incidence of the Philadelphia chromosome (Ph1) in older ALL patients (Hoelzer et 
al 1988).  
 
1.2.2.3 Rare Leukaemia Subtypes 
Hairy Cell Leukaemia (HCL) 
Some rarer types of leukaemia are not included in the acute/chronic and 
myeloid/lymphocytic classification system, one of which is hairy cell leukaemia (HCL). HCL 
is a lymphoid neoplasm that is one of the most treatable haematologic malignancies thanks 
to the development of effective agents such as nucleoside analogues and monoclonal 
antibodies (MoAbs) (Ravandi 2009). The median age for HCL presentation is about 55 years 
(the range is 24-81 years). The leukaemic cells affected are neoplastic B cells with 
cytoplasmic hair-like projections that infiltrate the bone marrow, liver, spleen and lymph 
nodes (Ravandi 2009). The nucleolus is not apparent or non-existent. Symptoms of HCL 
include anaemia, thrombocytopenia, leukopenia, pancytopenia and splenomegaly (Ravandi 
2009).  
 
T cell prolymphocytic leukaemia (T-PLL) 
TPLL is the most common type of mature T-cell leukaemia affecting adults, particularly men 
(Matutes and Estella 1998). It is characterised by a rapidly increasing peripheral blood 
lymphocyte count, bone marrow involvement and splenomegaly (Catoysky et al 2001). T-
PLL cells appear slightly larger than normal lymphocytes in peripheral blood or bone marrow 
aspirate smears. Also, each cell has a prominent nucleolus, irregular nuclear contours, and 
abundant non-granular and basophilic cytoplasm with protrusions or blebs (Garand et al 
1998). T-PLL cells are of mature T-cell lineage: positive for T-cell markers and negative for 
terminal deoxynucleotidyl transferase (TdT) (Valbuena et al 2005). The neoplastic cells are 
usually positive for CD4 and possibly CD8 also (Catoysky et al 2001).  
 
 
 
19 
 
Large granular lymphocytic leukaemia (LGLL) 
Large Granular Lymphocytes (LGLs) in normal adults make up 10-15% of the total 
peripheral blood mononuclear cells (Lamy et al 1998). LGL leukaemia (LGLL) is described 
as a clonal disorder involving blood, marrow and the spleen (Loughran et al 1985) and can 
be split into two LGLL disorders based on either the T-cell or NK-cell lineage. T-cell LGLL is 
a rare disease characterised by persistently increased circulating T-cell LGLs with a typical 
immunophenotype of CD3+, CD4 and CD8+ and cytogenic or molecular evidence of clonal 
T-cell lymphoproliferation (Loughran 1993). T-cell LGLL patients will show neutropenia and 
have recurrent infections (Semenzato et al 1997). Patients with systemic symptoms or 
infiltration of the spleen, liver, or bone marrow could be classified in the category of NK-cell 
leukaemia (Lubomir et al 2006).  
 
LGLL comprises 2-5% of all T-cell and NK-cell malignancies. T-cell LGLL cells often have a 
normal karyotype however when chromosomal aberrations occur, there is inversion of 12p 
and 14q, deletion of 5q and trisomy of chromosomes 3, 8 and 14 (Loughran et al 1985). In 
patients with NK-cell LGLL the most frequent clonal chromosomal abnormality is the deletion 
of the 6q chromosome. Patients are often treated with methotrexate, cyclophosphamide and 
cyclosporine in the first instance (Battiwalla 2003). Other therapies include treatment with 
prednisone, nucleoside analogues, haematopoietic growth factors (G-CSF, GM-CSF), 
antithymocyte globulin (ATG) and splenectomy, however this is only rare (Mercieca et al 
1994, Lamy et al 1995, Bargetzi et al 1996, Gentile et al 1996).  
 
Adult T-cell leukaemia (ATL) 
Human T-cell leukaemia/lymphoma virus type 1 (HTLV-1) causes neoplastic transformation 
of human T-cells in infected individuals, leading to development of adult T-cell leukaemia 
(ATL). Viral proteins act to increase the responsiveness of T-cells to extracellular stimulation, 
modulate proapoptotic and antiapoptotic gene signals, enhance T-cell survival, and avoid 
immune recognition of the infected T-cells (Franchini et al 2003). The virus disrupts several 
signalling pathways involved in immune function of T-cells thus promoting T-cell proliferation 
(Franchini et al 2003). Genetic changes such as the mutation of p53 and deletion of p16 
occur in some cases of ATL which give a poor prognosis (Yamada et al 1997). The 
immunological phenotype of neoplastic cells is helper T-cell, CD3+, CD4+, L-selectin+, 
CD25+, CD45RA+, HLA-DR+, CD29- and CD45RO- in peripheral blood (Tobinai et al 1992). 
Acute ATL is characterised by a massive infiltration of the peripheral blood by ATL cells, 
20 
 
while the ATL lymphoma is characterised by the presence of less than 1% leukaemic cells 
on a blood smear and major involvement of lymphoid organs (Nicot 2005).  
 
There are four types of ATLL (acute, chronic, smouldering and lymphoma) with varying 
symptoms and responses to treatment (Shimoyama 1991). Acute ATLL is for example 
characterised by symptoms such as fever, cough, lymphoadenopathy, skin lesions, 
hepatosplenomegaly, marked leukocytosis and hypocalcaemia which is frequently 
associated with lytic bone lesions and generalised bone resorption. The mean survival time 
for this specific disease is 6 months with a poor response to chemo- or radiotherapy (Nicot 
2005).  
 
1.3 Acute Myeloid Leukaemia 
1.3.1 Introduction 
Acute Myeloid Leukaemia (AML) is a heterogeneous clonal disorder of haemopoietic 
progenitor cells which lose the ability to differentiate normally and to respond to normal 
regulators of proliferation. With this and a decreased rate of self-destruction, cells 
accumulate in the bone marrow and other organs. Within a year of developing the disease, if 
treatment is not given, fatal infection, bleeding or organ infiltration will occur (Estey and 
Dohner 2006). Elderly patients do not survive treatment well and only reach a 10% cure rate 
due to cytogenetic abnormalities. Patients younger than 60 respond better to cytotoxic 
chemotherapies and have a cure rate ranging from 20-75%, again depending on leukaemia 
cell cytogenetics.  
 
It was proposed by McCulloch et al (1983) that there is an existence of leukaemia stem cells 
(LSCs) in AML. Studies have shown that only a small defined subset of leukaemic cells was 
consistently clonogenic and capable of generating leukaemia when transplanted in non-
obese diabetic severe combined immunodeficient (NOD/SCID) mice (Jordan 2007). 
Leukaemia is a disease determined by a few LSCs that undergo an aberrant and poorly 
regulated process of organogenesis analogous to that of normal haematopoietic stem cells 
(HSCs).  
 
AML is the most common myeloid leukaemia with a median age of presentation at 70 years 
and it is more prevalent in men than women. Risk factors for acquiring AML include benzene 
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exposure, most of which is received through cigarette smoking. Ionising radiation is another 
large risk factor, for example people who have survived atomic bombs have a greater risk 
due to abnormalities of chromosomes 5 and 7 (Nakanishi et al 1999). Also, AML is common 
in nuclear industry workers (Cardis et al 1995) and those who fly extensively in commercial 
jet planes (Gundestrup and Storm 1999). The third main risk factor for AML is cytotoxic 
chemotherapy. AML can develop after 5-10 years following exposure to alkylating agents 
which cause monosomies or deletions in chromosomes 5 or 7. AML can also develop 1-5 
years post-treatment with doxorubicin and etoposide, drugs which interact with DNA 
topoisomerase II, causing abnormalities in chromosome 11 and translocations between 
chromosomes 15 and 17 (Estey and Dohner 2006).  
 
Treatment for AML should be aggressive to achieve complete remission. Sixty to 70% of 
adults with AML may achieve complete remission following induction therapy and more than 
25% can expect to survive three or more years and may be cured (National Cancer Institute 
2010). Treatment consists of a combination of anthracyline drugs such as daunorubicin, 
idarubicin or cytarabine (Tallman et al 2005). There are two phases of therapy. The first 
phase involves drug treatment to attempt to produce complete remission. Complete 
remission is reached when marrow has less than 5% blasts, neutrophil count is greater than 
1000 and platelet count is greater than 100000 (Cheson et al 2003). The second phase aims 
to prolong the complete remission. Patients are treated with cytarabine or anthracycline. A 
remission length of three years means the likelihood of relapse falls to less than 10% (Estey 
and Dohner 2006). All treatment success depends on various factors relating specifically to 
the patient. Increased morbidity during induction appears to be inversely correlated with age 
(National Cancer Institute 2010). Other factors include central nervous system involvement 
with leukaemia, systemic infection at diagnosis, elevated white blood cell count 
(>100000/mm3), treatment-induced AML, history of myelodysplastic syndromes and other 
antecedent haematological disorders (National Cancer Institute 2010).  
 
1.3.2 French-American British classification system for AML  
The French-American-British (FAB) nomenclature system for AML helps to define which type 
of cell has become the leukaemic cell and also its degree of maturity. Morphology of 
cancerous cells are viewed by light microscopy or their cytogenetics are studied to define 
which category they come under. Different categories respond differently to treatment 
however other factors previously described such as age and previous treatment still 
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contribute to treatment outcome. This means each patient should be treated individually 
according to their health history, age and genetics, not just by AML subtype alone.  
 
Types of AML according to the FAB classification system range from M0 to M8. M0 is a 
minimally differentiated acute myeloblastic leukaemia which represents 2-3% of all cases of 
AML (Kumar et al 2007). The blasts in type M0 cannot be recognised as myeloid based on 
morphology and cytochemistry alone, however they are agranular and show no signs of 
having Auer rods. Immunophenotyping of M0 cells shows they have myeloid antigens such 
as CD13, CD33, CD34 and Human leukocyte antigen (HLA-DR) (Testa et al 2002). There is 
often loss of the long arm of chromosome 5 and 7 and higher expression of the multidrug 
resistance glycoprotein p170 (Lichtman et al. 2005).  
 
M1 
M1 is an acute myeloblastic leukaemia with too many immature white blood cells 
accumulating in the blood and bone marrow (Bennett et al 2008).  
 
M2 
M2 is acute myeloblastic leukaemia with granulocyte maturation. Patients generally display 
dysplastic features in myeloid and erythroid lineages with reduction in megakaryocytes (Taj 
et al 1995). Such characteristics are present in patients with a reciprocal translocation 
between chromosomes 8 and 21, t(8;21). The DNA before translocation would normally 
code for two separate proteins RUNX1 and ETO, however translocation causes the two 
proteins to be transcribed and translated into a single large protein known as M2 AML. This 
allows the cell to divide unchecked which leads to the development of leukaemia (Taj et al 
1995).  
 
M3 
M3 is an acute promyelocytic leukaemia (APL) where an abnormal number of immature 
promyelocytes accumulate in the blood. M3 AML is characterised often by a chromosomal 
translocation between the retinoic acid receptor alpha gene on chromosome 17 (RARα) with 
the promyelocytic leukaemia gene (PML) on chromosome 15, t(15;17)(q22;q12) (Pecorino 
2008). The fusion protein binds with enhanced affinity to sites on the cell’s DNA, this 
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enhances interaction of nuclear co-repressor molecule with histone deacetylase, which in 
turn blocks transcription and differentiation of graulocytes (Rambaldi 2002).  
 
A particular symptom of APL is coagulopathy which is the susceptibility to excessive 
bleeding and insufficient blood clotting. The majority of APL patients are affected by 
disseminated intravascular coagulation (DIC) (Tallman et al 1993). This is due to 
hypofibrinogenemia, increased fibrinogen-fibrin degradation products (FDP), and prolonged 
prothrombin and thrombin times (Barbui et al 1998). APL is also characterised by the 
presence of faggot cells. The cytoplasm of faggot cells contains multiple Auer rods 
(Lazarchick 2009). Auer rods are cytoplasmic inclusions found only in the leukocytes of AML 
(Pearson 1986). Auer rods appear as clumps of asurophilic granular material that 
aggregates in elongated needles in the cytoplasm of leukaemic blasts. They are composed 
of fused lysosomes and contain peroxidise, lysosomal enzymes and large crystalline 
inclusions (Hütter et al 2007). 
 
M4 
AML type M4 is known as acute myelomonocytic leukaemia (AMMoL) or AML-M4 with bone 
marrow eosinophilia (AML M4Eo). This FAB category commonly has abnormalities of 
chromosome 16q22, for example: del(16)(q22), inv(16)(p13q22) and t(16;16)(p13;q22) 
(Arthur et al 1983, Le Beau et al 1983 and Testa et al 1984). Patients with AML M4Eo have 
a young median age (Bernard et al 1989) and often have a high peripheral white blood cell 
count and organomegaly and generally have a high response rate to induction 
chemotherapy (Adriaansen et al 1993). Relapses occur in the central nervous system 
relatively frequently as leptomeringeal disease and intracerebral myeloblastomas (Holmes et 
al 1985). Blast cells, monocytic cells and eosinophil cells can be recognised within each 
AML M4Eo. Eosinophils are often dysplastic with abnormal eosinophilic granules and 
varying numbers of basophilic-staining granules (Holmes et al 1985).  
 
M5 
AML type M5 is further divided into two subtypes: AML M5a (acute monoblastic leukaemia) 
and 5b (acute monocytic leukaemia). Both are defined when 80% or more of the leukaemic 
cells are monocytic in their lineage, including monoblasts, promonocytes and monocytes. To 
distinguish between the two, the relative proportions of monoblasts and promonocytes are 
noted. In type 5a, 80% or more of the monocytic cells are monoblasts whereas in type 5b, 
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the majority of monocytic cells are promonocytes (Brunning et al 2001). Type 5a AML has 
more frequent aberrations of 11q23/MLL than type 5b, and both have higher frequencies 
than all other AML subtypes (Haferlach et al 2002). Chromosome abnormalities of 11q23 
have been related to poor prognosis and short, event-free survival (Thirman et al 1993). 
There is also a higher incidence of FLT-3 length mutations in AML 5b compared with AML 
5a (Haferlach et al 2002).  
 
M6 
AML type M6 is known as acute erythroleukaemia, a rare subtype of AML with poor 
prognosis and commonly associated with previous diagnosis of myelodysplastic syndrome 
(MDS) (Santos et al 2009). Jogai et al (2001) have found blasts in peripheral blood, 
dyserythropoiesis, dysmegakaryopoiesis and dysplasia in granulocytic cells in many M6 
AML patients. Many M6 AML cases have an anomaly named chromosome torsion by Glaser 
et al. Such an anomaly consisted of the chromatids of the p- and q-arm being located side 
by side rather than in the usual tandem alignment.  
 
M7 
Type M7 AML is known as acute megakaryoblastic leukaemia. Children with constitutional 
trisomy 21 (Down’s syndrome) have a 500-fold increased risk of developing acute 
megakaryoblastic leukaemia (Hitzler et al 2003). Hitzler et al have found somatic mutations 
of the gene encoding the haematopoietic transcription factor GATA1 in acute 
megakaryoblastic leukaemia blasts of patients with Down’s syndrome which has suggested 
a significant role for these mutations in the development of leukaemia. Type M7 AML 
typically has a translocation of chromosome 22 involving the megakaryocytic acute 
leukaemia (MAL) gene (Mercher et al 2001).  
 
M8 
Finally, type M8 AML is known as acute basophilic leukaemia (ABL) and is another rare form 
of acute leukaemia. Blast cells are morphologically undifferentiated and coarse basophilic 
granules can be recognised. Myeloid antigens such as CD9 or CD25 are strongly expressed 
however lymphoid, erythroid or megakaryocytic markers are not expressed significantly. 1-A 
pure ABL is a type of monophenotypic ABL where only the basophilic lineage is affected. 
This is classified as AML M8, which has suspected c-MYB (myeloblastosis) oncogene 
involvement (Duchayne et al 1999).  
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Intro Figure 2: The subtypes of AML according to the FAB classification system. Left to right, 
top to bottom: M1, M2, M3, M4, M5, M6, M7, M8. 
 
 
1.3.3 World Health Organisation classification system for AML  
The FAB classification system is not always used to define AML type because it is based on 
bone marrow and peripheral blood blast counts without considering clinical and biological 
variables such as cytogenetics and the degree and number of cytopenias (Lee et al 2003). 
Also, in many cases there may be no correlation between cell morphology and genetic 
defects or underlying genetic and molecular defects cannot be identified (Vardiman et al 
2002). There also exists the World Health Organisation (WHO) classification system of AML 
which aims to give more helpful clinical and prognostic information. WHO classification for 
AML is shown in Intro Table 1 (Vardiman et al 2002).  
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1. Acute myeloid leukemia with recurrent genetic abnormalities  
 Acute myeloid leukemia with t(8;21)(q22;q22), (AML1/ETO)   
 Acute myeloid leukemia with abnormal bone marrow eosinophils and 
inv(16)(p13q22) or t(16;16)(p13;q22), (CBFβ/MYH11)   
 Acute promyelocytic leukemia with t(15;17)(q22;q12), (PML/RARα) and 
variants   
 Acute myeloid leukemia with 11q23 (MLL) abnormalities   
2. Acute myeloid leukemia with multilineage dysplasia   
 Following MDS or MDS/MPD   
 Without antecedent MDS or MDS/MPD, but with dysplasia in at least 50% of 
cells in 2 or more myeloid lineages   
3. Acute myeloid leukemia and myelodysplastic syndromes, therapy-related  
 Alkylating agent/radiation–related type   
 Topoisomerase II inhibitor–related type (some may be lymphoid)   
 Others   
4. Acute myeloid leukemia, not otherwise categorized   
 Acute myeloid leukemia, minimally differentiated   
 Acute myeloid leukemia without maturation   
 Acute myeloid leukemia with maturation   
 Acute myelomonocytic leukemia   
 Acute monoblastic/acute monocytic leukemia   
 Acute erythroid leukemia (erythroid/myeloid and pure erythroleukemia)   
 Acute megakaryoblastic leukemia   
 Acute basophilic leukemia  
 Acute panmyelosis with myelofibrosis   
 Myeloid sarcoma 
 
Intro Table 1: WHO classification of AML 
 
1.4 Apoptosis 
1.4.1 Introduction 
AML in particular is a disease that is greatly affected by the amount of apoptosis occurring in 
the cancerous cells. Generally, there is a decreased rate of self-destruction of white blood 
cells which leads to an accumulation of these cells in the bone marrow and in other organs. 
This is the cause behind many of the symptoms of AML including increased frequency of 
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infection and increased bruising. This chapter will explain the link between apoptosis and 
leukaemia on a molecular level.  
 
Apoptosis is a homeostatic mechanism of programmed cell death that occurs throughout 
normal development and ageing to maintain steady and healthy cell populations in tissues. 
Cells are threatened by bacterial and viral diseases, and also by cytotoxic and mutagenic 
effects of DNA damaging agents such as: UV light, ionising radiation, chemicals in 
foodstuffs, air- and water-borne agents, methylating species and reactive oxygen species 
(Norbury et al 2001). Damaged DNA within cells must be repaired, or the cell must undergo 
apoptosis to ensure the damage is not replicated and passed on to daughter cells.  
 
Intro Figure 3: Cellular signalling leading to apoptosis [www.cellsignal.com]. 
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1.4.2 Apoptosis and leukaemia 
Many forms of leukaemia involve a continuous increase in white blood cells counts due to 
defects in apoptotic machinery rather than increased cell proliferation alone (Kitada et al 
1998). For example, B-cell chronic lymphocytic leukaemia (B-CLL) is characterised by the 
accumulation of resting, long-lived, CD5+ B cells in blood which express high levels of the 
antiapoptotic proteins such MCL-1 and BCL-2 (Robertson 1996). BCL-2 is a proto-oncogene 
which delays the onset of apoptosis in cells. BCL-2 over expression is associated with 
resistance to chemotherapy and inhibition of apoptosis (Panayiotidis 1993). When CLL cells 
are cultured in vitro, cells with high levels of BCL-2 survive longer than those with low levels 
which suggests an inherent survival advantage by BCL-2 (Kumudha et al 2010). MCL-1 is an 
oncogene that promotes tumorigenesis and protection against apoptosis and drug resistance 
of malignant cells. MCL-1 expression is required in tumours to maintain cell viability and 
promote cell differentiation, and its down-regulation induces apoptosis (Adida et al 2000). 
 
CML has a translocated Philadelphia chromosome, forming the hybrid Bcr-ABL protein, an 
oncoprotein which is believed to inhibit the apoptotic response, providing a survival 
advantage for the leukaemic cell clone (Sears et al 2010).  
 
In AML and other lymphoid malignancies, glucocorticoids (GCs) are common components of 
many chemotherapeutic treatments. Upon relapse however, patients can become resistant 
to GC treatment due to defects in apoptotic machinery (Tissing et al 2003). Heidari et al 
(2010) have recently shown that down regulation of the antiapoptotic BCL-2 family proteins, 
particularly MCL-1, enhances GC-induced cell death. MCL-1 is targeted by GX15-070 
(obatoclax) which induces caspase-3 cleavage and increases a population of Annexin V-
positive cells (Heidari et al 2010).  
 
Lu et al (2006) and Heidari et al (2010) have shown that BIM, a pro-apoptotic BH3-only 
protein, is up regulated by treatment with dexamethasone (Dex) in ALL cells. BIM plays an 
important role in Dex-induced apoptosis (Lu et al 2006). Co-treatment with Dex and 
MEK/ERK inhibitors both up regulates BIM and aids BIM dephosphorylation/activation, 
promoting apoptosis in a variety of ALL cells (Rambal et al 2009).  
 
Gonzalez et al (2010) have investigated the effect that Heat-shock protein-27 (Hsp27) on 
leukaemic cells. Hsp27 associates with components of the extrinsic and intrinsic apoptotic 
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pathways and inhibits the execution of apoptosis. Elevated expression of Hsp27 accentuates 
tumorigenicity and the resistance to chemotherapy of malignant cells (Hansen et al 1999) 
which is why high expression of Hsp27 in leukaemia is associated with a bad prognosis 
(Thomas et al 2005). Gonzalez et al (2010) have recently shown that apigenin, a common 
plant dietary flavonoid found in parsley and celery, can be used as an anti-cancer compound 
against Hsp27. Apigenin induces phosphorylation of Hsp27 which modulates its 
oligomerisation properties thus modulating the cytoprotective activity of Hsp27 (Kato et al 
1994). Apigenin also has cytotoxic flavonoid activity against Hsp-27 which is more effective 
following the phosphorylation step (Gonzalez et al 2010) 
 
Survivin, an inhibitor of apoptosis protein, is over expressed in the blasts of AML patient 
samples (Carter et al 2001). Survivin suppresses cell death induced by a variety of stimuli 
including tumour necrosis factor (TNF), Fas, menadione, staurosporine, etoposide, paclitaxel 
and growth factor withdrawal (Ambrosini et al 1997). Disruption of survivin expression 
causes cell death and cell division defects, resulting in polyploidy and multinucleated cells 
(Fraser et al 1999). XIAP is another inhibitor of apoptosis protein whose expression levels in 
primary AML samples is variable and is found to be inversely correlated with AML patient 
survival (Tamm et al 2000).  
 
Finally, NF-κB signalling largely affects the outcome of a cells response to apoptotic signals. 
Activation of NF-κB is required for a successful immune response and to amplify the survival 
and proliferation of cells (Demchenko et al 2009). NF-κB has been found to be constitutively 
active in most tumour cell lines (Aggarwal 2004) which allows NF-κB to mediate 
inflammation and tumorigenesis and prevent a sufficient level of apoptosis required to 
maintain a healthy number of blood cells present in the population. 
 
1.5 Nuclear Factor-kappaB 
1.5.1 Introduction 
NF-κB (or nuclear factor for the kappa-light-chain-enhancer of activated B cells) was 
discovered by David Baltimore in 1986 via its binding to a sequence in the kappa light chain 
enhancer in B cells.  Proteins in the NF-κB family are dimeric transcription factors composed 
of five different subunits: p65 (RelA), RelB (p65), cRel, p50 and p52 (Harald et al 2010). 
They control cellular responses such as inflammation, immune response, differentiation, 
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proliferation and apoptosis (Kempe et al 2005). NF-κB proteins do this in response to stimuli 
such as stress, cytokines, free radicals, ultraviolet radiation, oxidised low density lipoproteins 
(LDLs), and bacterial or viral antigens (Brasier et al 2006). Normally, NF-κB has a role in 
regulating the immune response to infection, however NF-κB can become dysregulated 
leading to cancer, inflammatory and autoimmune diseases, septic shock, viral infection and 
improper immune development.  
 
1.5.2 NF-κB proteins and their structure 
NF-κB 1 and NF-κB 2 proteins are different in that they are synthesised as large precursors 
p105 and p100 which undergo processing to become the mature p50 and p52 subunits. This 
processing is mediated by the ubiquitin/proteasome pathway and involves selective 
degradation of their C-terminal region which contains inhibitory ankyrin repeats (Gilmore et 
al 2006). While the generation of p52 from p100 is a tightly regulated process, p50 is 
produced from constitutive processing of p105 (Karin et al 2000). 
 
All proteins in the NF-κB family have a conserved DNA-binding/dimerisation domain called 
the Rel homology domain (RHD) in their N-termini (Intro Figure 3). The RHD contains a 
nuclear localisation sequence (NLS) which is involved in dimerisation, sequence specific 
DNA binding and interaction with the inhibitor IκB proteins (Ghosh et al 1998). NF-κB dimers 
bind to κB sites within the promoters/enhancers of target genes and regulate transcription 
through the recruitment of co activators and co repressors (Hayden and Ghosh 2008). A 
subfamily of NF-κB proteins including RelA, RelB and c-Rel have a transactivation domain 
(TAD) in their C-termini, which also has sequences important for nuclear localisation and IκB 
inhibitor binding (Gilmore et al 2006). p50 and p52 may repress transcription unless 
associated with a TAD-containing NF-κB family member, as they do not have a TAD of their 
own (Hayden and Ghosh 2008). 
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Intro Figure 3: Structure of core NF-κB signalling proteins. [Gilmore 2006]. 
 
1.5.3 NF-κB signalling 
In un stimulated cells, NF-κB proteins normally reside in the cytoplasm in an inactive state 
where their nuclear localisation sequence (NLS) is masked by either one of two ways 
(Hayden et al 2008). The different ways in which the NLS of NF-κB proteins is masked 
distinguishes between the canonical and non-canonical NF-κB signalling pathways. In the 
canonical or classical pathway, a dimer of NF-κB interacts intermolecularly with an inhibitor 
of κB (IκB) protein forming an inactive ternary complex (Scheidereit et al 2006). In the non-
canonical or alternative NF-κB signalling pathway, blockade of the NLS occurs by 
intramolecular binding of an inhibitory domain. The inhibition comes from the IκB protein-like 
inhibitory domains on the C-terminal parts of the large 105 and 100 kDa precursor proteins 
of NF-κB subunits p50 and p52 (Ghosh et al 1998 and Scheidereit et al 2006). Receptor-
mediated activation of the canonical NF-κB pathway occurs within a matter of minutes and 
does not require new protein synthesis, however activation of the non-canonical NF-κB 
pathway takes several hours and does require new protein synthesis of NIK (Matsuhima et 
al 2001 and Zarnegar et al 2008).  
Key:  
RHD – Rel homology domain 
TAD – Transcriptional activation 
domain 
S – Serine residue 
HLH – Helix loop helix 
LZ – Leucine zipper 
NBD – NEMO binding domain 
CC – coiled coil 
ZF – zinc finger 
 O – ankyrin repeat 
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1.5.3.1 The non-canonical or alternative NF-κB signalling pathway 
The non canonical pathway is activated by lymphorganogenic cytokines, such as 
lymphotoxin-α-β-heterotrimers, and B cell survival and maturation factors, such as CD40 
ligand (CD40L) and BAFF (B cell activating factor)(Derudder et al 2003 and Claudio et al 
2002). Lymphotoxin-α-β, CD40L and BAFF belong to the TNF super family whose members 
signal through trimeric receptors (TNF receptors or TNFRs) and signalling proteins called 
TNFR-associated factors (TRAFS) (Bishop et al 2004). Other members of the TNF super 
family which signal in this way are RANKL (receptor activator of NF-κB ligand) and TWEAK 
(TNF-related weak inducer of apoptosis) (Claudio et al 2002). TRAFS are the key 
intermediates in both the classical and alternative NF-κB signalling pathways (Hacker et al 
2006).  
 
Activation of the non-canonical NF-κB signalling pathway requires degradation of TRAF 
proteins. TRAF2 and TRAF3 are inhibitors of non-canonical NF-κB signalling (Gardam et al 
2008). Activation of the non-canonical pathway depends on receptor-induced TRAF3 
degradation and stabilisation of NIK (Liao et al 2004) as TRAF3 is a negative regulator of the 
activation of NIK. In the resting state, TRAF3 induces NIK ubiquitination and degradation 
(Liao et al 2004). Upon receptor activation, TRAF2 ubiquitinates and activates cIAP1 and 
cIAP2 to induce degradative Lys48-linked polyubiquitination of TRAF3. cIAP1 and cIAP2 are 
RING-containing components of the non-canonical pathway which belong to the IAP 
(inhibitors of apoptosis) family (Vallabhaparpu et al 2008). Degradation of TRAF3 prevents 
targeting of newly synthesised NIK by a TRAF2-cIAP1-cIAP2 ubiquitin ligase complex, 
allowing NIK accumulation and activation through autophosphorylation (Vallabhaparpu et al 
2008).  
 
NIK (NF-κB inducing kinase) is a positive regulator of the processing of the NF-κB 2 gene 
product p100 into the mature NF-κB subunit p52 (Xiao et al 2001). P100 has several 
properties that are likely to be important for NF-κB regulation: selective regulation of specific 
NF-κB complexes such that in its absence, a subset of inducible NF-κB responses (e.g. 
RelB-dependent gene expression) is lost; selective function of IκB subunits downstream of 
specific signalling pathways; and regulation of basal activity of specific NF-κB dimers 
(Hayden and Ghosh 2008). NIK is a potent and specific inducer of p100 processing which 
acts via IκKα subunits only, IκBβ and NEMO are not involved (Hacker and Karin 2006). NIK 
directly phosphorylates and activates IκKα (Hacker and Karin 2006)which then induces site-
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specific phosphorylation of p100 by IκKα and ubiquitination of p100. This leads to p100 
processing (as opposed to degradation) in the 26s proteasome, producing the mature p52 
NF-κB subunit (Xiao et al 2001).  
 
Constitutive processing of p100 is suppressed by a processing-inhibitory domain (PID) which 
can be found at the C-terminal region of p100 (Xiao et al 2001). A low level of constitutive 
processing of p100 to p52 does however occur in a cell type-specific manner. This is also 
dependent on IκKα and NIK (Qing and Xiao 2005 and Xiao et al 2004). Once the mature p52 
subunit has been generated, it will associate with RelB to gain the use of RelB’s TAD 
domain, then translocate into the nucleus as a heterodimer. p52 containing NF-κB dimers 
drive a transcriptional response that is distinct from that induced by the canonical, IκBα-
regulated pathway (Hayden and Ghosh 2008). Because p100 undergoes constitutive 
processing in certain tissues, RelB/p52 heterodimers may exhibit constitutive activation.  
 
1.5.3.2 The classical or canonical NF-κB signalling pathway 
 
The canonical NF-κB pathway is initiated by activation of the TRAF adaptor proteins and the 
subsequent stimulation of the IκB kinase (IKK) complex which contains the kinases IκKα, 
IКKβ and the structural/regulatory component NEMO or IκKγ (Hayden et al 2008). The NF-
κB precursor protein p105 undergoes processing via the proteasome to give the mature 
subunit p50 (Moorthy et al 2006). When p105 is bound to NF-κB complexes, it appears that 
processing is inhibited and instead induced degradation is favoured (Cohen et al 2001). This 
means that unprocessed p105 acts as an IκB protein that binds NF-κB dimers and can be 
inducibly degraded upon IκK activation (Hayden and Ghosh 2008). The activated IκK 
complex phosphorylates IκB proteins which triggers their rapid proteasomal degradation. IκB 
proteins in un stimulated cells provide inhibition by masking the NLS of p65 which 
sequesters the NF-κB dimers away from κB elements and inhibits transcription (Hayden and 
Ghosh 2008). IКB protein degradation leaves the NF-κB p65:p50 dimers free from inhibition 
in the cytoplasm as the NLS of both p50 and p65 subunits become exposed, allowing them 
to translocate into the nucleus. Cells that lack all three IκB subunits show relatively normal 
nuclear and cytoplasmic p65 distribution but significantly increased basal NF-κB dependent 
gene expression. This suggests that regulation of the transcriptional activity of NF-κB by 
IκBs is partly independent of cytoplasmic sequesteration (Tergaonkar et al 2005).  
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Downstream of IκB degradation, it has been shown that phosphorylation of p65 by protein 
kinase A (PKA) is crucial for NF-κB transcriptional activity (Chen and Greene 2004). PKA 
can be found in a complex with cytosolic NF-κB :IκB complexes and phosphorylates p65 at a 
serine residue after degradation of IκBα. This promotes the interaction of p65 with the 
transcriptional co activators CREB-binding protein (CBP) and p300 (Zhong et al 1998). 
There are also other kinases such as MSK1 and MSK2 (mitogen- and stress-activated 
protein kinase) which phosphorylate serine residues of p65 (Hayden and Ghosh 2008). 
Finally, IκKα and IκKβ are involved in the direct phosphorylation of p65 (Chen and Greene 
2004) and CK2 inducibly phosphorylates p65 following IL-1 or TNFα stimulation (Bird et al 
1997). p65 can increase transcription when it is acetylated by CBP/p300 and associated 
histone acetylases (HATs) (Chen and Greene 2004). The acetylation of a particular lyseine 
(Lys310) has most clearly been shown to enhance transcriptional activity without altering 
DNA or IκB binding (Chen et al 2002)  
 
To summarise, in the non-canonical NF-κB pathway TRAF and NIK are sufficient to activate 
IκKα in a NEMO-dependent manner. In the canonical NF-κB signalling pathway, signalling 
relies on both TRAF and RIP proteins as well as the kinase TAK1. NEMO is required for 
signalling in all canonical NF-κB pathways. Pathways may be categorised as non-canonical 
and canonical based on the requirement for NEMO or on the specific IκB protein that is 
phosphorylated and degraded/processed. IκBα, IκBβ and IκBε for canonical and p100 for 
non-canonical. All aspects of the NF-κB signalling pathway are shown in the figure below.  
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Intro Figure 4: Components of the canonical, non-canonical and alternate NF-κB signalling 
pathways. [Gilmore 2006]. 
 
1.5.4 Termination of the NF-κB response 
Transcription of target genes is regulated through posttranslational modifications of NF-κB 
that affect the ability of NF-κB dimers to interact with transcriptional co-activators. NF-κB -
dependent transcription of IκB proteins and additional mechanisms targeting DNA-bound 
NF-κB dimers terminate the response (Hayden and Ghosh 2008). Active, DNA-bound NF-κB 
is suppressed once signalling is terminated. This is possibly done when promoter-bound p65 
may be subject to proteasomal degradation (Saccani et al 2004). IκKα is also involved in 
termination of inflammatory transcriptional responses in macrophages, possibly by 
promoting the nuclear degradation of both p65 and c-Rel (Lawrence et al 2005, Li et al 
2005).  
 
1.5.5 TNF-induced NF-κB signalling 
TNFα binds to TNFR1 which recruits TRAF2 to the receptor through its interaction with 
TRADD (Hsu et al 1996). TRAF2 has E3 ubiquitin ligase activity and TRAF5 is also involved 
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with TNFR1 signalling (Nakano et al 1999). IκK may be recruited to the TNFR1 receptor 
through RIP1 kinase (Hayden and Ghosh 2008). RIP family kinases are characterised by 
their conserved serine/threonine kinase domains (Meylan and Tschopp 2005). There are 
seven RIPs in the family and RIP1 has a death domain (DD) which mediates interaction with 
other death domain-containing adaptors and receptors (Hayden and Ghosh 2008). 
Receptor-interacting proteins (RIPs) act both upstream of and with TRAF proteins to activate 
IκK. RIP proteins act as true adaptors in NF-κB signalling pathways by interacting with 
upstream signalling cassettes through well characterized protein-binding domains. RIP1 
binds to NEMO and is essential for TNFα-induced IκK and NF-κB activation (Hsu et al 1996 
and Kelliher et al 1998).  
 
1.5.6 NF-κB and cancer 
The activation of NF-κB can produce both beneficial and damaging effects on human health. 
While NF-κB is needed for proper immune system function, inappropriate NF-κB activation 
can mediate inflammation, tumour cell survival, proliferation, invasion, angiogenesis and 
metastases (Kunnumakkara 2009). Inflammatory agents, carcinogens, tumour promoters 
and the tumour microenvironment can activate NF-κB (Bharti and Aggarwal 2002). Cancer is 
a pro-inflammatory disease (Balkwill and Mantovani, 2001) and most inflammatory agents 
mediate their effects through the activation of NF-κB.  
 
NF-κB is rarely found to be constitutively active in normal cells except for proliferating T 
cells, B cells, thymocytes, monocytes and astrocytes. NF-κB is however constitutively active 
in tumour tissues derived from patients with multiple myeloma (Feinman et al 1999), AML 
(Griffin 2001), ALL (Kordes et al 2000), CML, (Baron et al 2002) and prostate (Palayoor et al 
1999) and breast cancers (Nakshatri et al 1997). The constitutive activation of NF-κB may be 
caused by mutation of IκBα (Wood et al 1998), enhanced proteasomal activity (Miyamoto et 
al 1994), or enhanced inflammatory cytokine expression (O’Connel et al 1995). This may 
occur as a result of the effects of the carcinogens such as DMBA and cigarette smoke, and 
of tumour promoters such as phorbol esters (Banerjee et al 2002 and Anto et al 2002). TNF 
may be the most potent activator of NF-κB, it mediates carcinogenesis through induction of 
proliferation, invasion and metastasis of tumour cells (Shishodia et al 2003). c-Rel itself is an 
oncogenic protein of the NF-κB family which is found to be amplified in Hodgkin’s 
lymphomas, diffuse large B cell lymphomas, and some follicular and mediastinal B cell 
lymphomas (Gilmore et al 2004). Other oncogenes involved in cellular transformation via the 
effects of NF-κB include Ras, c-myc, Pim-2, Kaposi’s sarcoma-associated herpes virus 
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(KSHV) proteins, EBV latent membrane protein (LMP)-1 and human T lymphocytic 
leukaemia virus (HTLV)-1 (Aggarwal 2004).  
 
Both cytokines and cytokine receptors either are regulated by NF-κB or mediate proliferation 
through activation of NF-κB (Aggarwal 2004). For example IL-1β is a growth factor for AML 
and it activates NF-κB to mediate its proliferative effects (Osborn et al 1989). NF-κB 
activation also has a role in mediating angiogenesis and cellular invasion in tumours. Gene 
products involved in tumour invasion such as matrix metalloproteinases (MMP), urokinase 
type of plasminogen activator (uPA) and interleukin-8 (IL-8) are regulated by NF-κB 
signalling, particularly the degradation of IκBα (Novak et al 1991). Growth factors controlled 
by NF-κB activation that regulate angiogenesis are VEGF, TNF, IL-1 and IL-8 which are 
produced by macrophages, neutrophils and other inflammatory cells (Loch et al 2001). NF-
κB regulates the expression of various adhesion molecules including ICAM-1, VCAM-1 and 
ELAM-1 (van de Stolpe et al 1994) which mediate metastasis of cancerous cells, along with 
inducible nitric oxide synthase (iNOS) (Thomsen and Miles 1998).  
 
Inflammation mediates tumorigenesis. NF-κB links this relationship in various ways. Greten 
et al (2004) demonstrated expression of IκKβ in enterocytes is important during early stages 
of tumour initiation and promotion by expression of antiapoptotic proteins whereas in myeloid 
cells, IκKβ contributed to initiation and promotion through expression of tumour growth 
factors. Activation of NF-κB by endotoxin in cancer cells produces inflammation-induced 
tumour growth through expression of TNF and inhibition of NF-κB mediates tumour 
regression through TRAIL (Luo et al 2004). NF-κB activation is required for LPS-induced 
tumour growth in the CT26 colon cancer cell line and TNF mediates LPS-induced tumour 
growth and NF-κB activation (Luo et al 2004).  
 
The p53 protein has long been implicated at multiple levels with the NF-κB pathway. The 
importance of both NF-κB and p53 in cancer has promoted significant research into the 
relationship between these two transcription factors (Hayden and Ghosh 2008). P53 and p65 
have been reported to directly compete for CBP/p300 (Webster and Perkins, 1999) which 
has been suggested to promote their cross-repression.  
 
Deregulation of NF-κB activity has been increasingly implicated in neoplastic transformation 
and cancer progression (Sun and Xiao 1993). Adult T cell leukaemia can be caused by 
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infection by human T cell leukaemia virus type 1 (HTLV-1). HTLV-1 has a viral protein Tax 
which persistently activates NF-κB . Tax protein works by activating the IκK complex in a 
NEMO-dependent manner (Yamaoka et al 1998). Tax physically interacts with p100, this 
recruitment leads to the phosphorylation and processing of p100 (Xiao et al 2001). Tax 
however is not detectable in fresh ATL cell samples and ATL-derived cell lines despite there 
being reported constitutive IκK activity and aberrant expression of p52 in such ATL cells 
(Hironaka et al 2004). Such findings have suggested that Tax-independent constitutive NF-
κB activation in ATL cells involves the non-canonical signalling pathway (Miura et al 2005). 
This theory has been supported by findings from that NIK is over-expressed at the pre-
translational level in ATL (Saito et al 2008).  
 
1.5.7 NF-κB and chemotherapy resistance 
It has been shown by many investigations that NF-κB is constitutively activated in several 
human tumours (Camp et al 2003). NF-κB activation may play a role in oncogenesis by 
stimulating cell growth and inhibiting apoptosis and providing a survival advantage for 
transformed cells (Camp et al 2003). NF-κB liberation allows nuclear translocation and 
subsequent induction of target genes that code for cell cycle regulatory genes such as cyclin 
D1 that stimulate cell proliferation and antiapoptotic proteins such as survivin (Hinz et al 
1999).  
 
Chemotherapy and radiation therapies are generally targeted to components of the apoptotic 
pathway however it has become obvious that NF-κB has a role in inducible chemoresistance 
(Camp et al 2003). Unfortunately, agents such as cytokines, chemotherapeutic agents and 
radiation that induce apoptosis also activate NF-κB (Beg and Baltimore 1996). This indicates 
that NF-κB is part of the auto-defence mechanism of the cell thus may mediate 
desensitisation, chemoresistance and radioresistance (Wang et al 1999). 
 
Most chemotherapeutic drugs used today activate NF-κB and induce resistance to 
chemotherapeutic agents. NF-κB mediates chemoresistance by its close relationships with 
MDR1, COX-2, survivin, Bcl-2/bcl-xL, IAP-1, IAP-2, XIAP, cFLIP, adhesion molecules, 
AKT/PI3K, mTOR signaling, PTK, 5-LOX, EGFR, IL-6, HER-2, PKC/PKA, cyclin D1, C-myc, 
integrins,and STAT3. Aspirin is an established NF-κB blocker and an anti-inflammatory 
agent shows promise in the treatment of certain cancers. Blockers of NF-κB such as 
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polyphenols are nontoxic and should be beneficial both in the prevention and treatment of 
cancer (Aggarwal et al 2004).  
 
1.5.8 NF-κB activation prevents tumorigenesis 
It appears thus far that NF-κB would be a perfect target for anti-cancer therapies however 
NF-κB has a dual nature in which either its activation or inactivation may lead to 
tumorigenesis (Aggarwal 2004). For example, NF-κB mediates a switch from cell 
proliferation in basal cells of the epidermis to growth arrest and differentiation in suprabasal 
cells (Seitz et al 1998). If the pharmacologic inhibitor of NF-κB is applied to intact skin, 
epidermal hyperplasia occurs (Seitz et al 1998) showing that in this tissue NF-κB is 
important for cellular growth inhibition. Another study by Dajee et al (2003) has shown that 
blocking NF-κB triggers invasive human epidermal neoplasia because in normal human 
epidermal cells NF-κB triggers cell-cycle arrest.  
 
1.5.9 NF-κB and AML 
 
When healthy monocytes and macrophages receive signalling from TNF, NF-κB becomes 
activated which protects these cells from apoptosis via transcription of antiapoptotic genes 
such as Fas-associated protein with death domain-like interleukin-1 (IL-1)-converting 
enzyme (FLICE/caspase-8)-inhibitory protein (FLIP) and inhibitor of apoptosis-1 (Tucker et al 
2004). Such healthy cells can become sensitive to cell death signals after the inhibition of 
NF-κB following treatment with anti-TNF (Liu et al 2004).  
 
In AML cells however, there is a limited effect of NF-κB inhibition on apoptosis following 
treatment with anti-TNF (Rushworth et al 2008). This inability to induce apoptosis comes 
from the cytoprotective gene heme oxygenase-1 (HO-1). HO-1 is induced in response to NF-
κB inhibition and superinduced when in combination with TNF activation. When HO-1 
expression is inhibited, AML cells become susceptible to TNF-induced apoptosis (Rushworth 
et al 2008).  
 
TNF is a recognised activator of NF-κB which in AML cells protects transformed cells from 
cell death.  
 
AML blasts have constitutive NF-κB activation (Guzman et al 2001) which protects the 
leukaemic cells from apoptosis. This protective effect can be removed by inhibiting NF-κB 
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signalling which can be done by treating AML cells with proteasome inhibitors, which rapidly 
induces cell death (Guzman et al 2001). Another method by which NF-κB has been inhibited 
is with dominant-negative alleles of the NF-κB regulatory molecule IκBα (Epinat et al 1999).  
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1.6 AIMS 
 
The aim of this work was to understand the significance of NF-κB in human AML by:  
 Comparing the expression levels of NF-κB signalling components between human 
AML samples and control cells 
 Understanding the mechanism controlling IκB expression relative to other NF-κB 
signalling components.  
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Chapter 2: Materials and Methods 
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2.1 Human Research/Patient Rights 
Primary AML cells were obtained under local ethical approval (LREC ref 07/H0310/146). 
Informed consent was obtained from patients and any identifying information was 
anonymised according to the approved ethics code of practice. 
 
2.2 Materials 
The AML-derived cell lines THP-1, HL60, U937, and AML 193 cells were obtained from the 
European Collection of Cell Cultures. Recombinant human TNF was purchased from R&D 
Systems (Minneapolis, MN). Antihuman HO-1 antibody was purchased from Assay Designs 
(Ann Arbor, MI). Antihuman FLIP antibody was purchased from Abcam (Cambridge, MA). All 
other antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). All other 
reagents were obtained from Sigma-Aldrich (St Louis, MO), unless indicated. 
 
2.3 Methods 
2.3.1 Cell culture 
All cells including cell lines, AML primary cells and primary control cells were cultured in 
RPMI-1640 supplemented with 10% FCS and 1% L-glutamine and incubated in a humidified 
atmosphere at 37˚C with 5% CO2. AML cells were obtained from AML bone marrow 
following the protocol described below. AML bone marrow samples were obtained from the 
Norfolk and Norwich University Hospital.  
 
2.3.2 Isolation of AML cells 
Blood from AML patients was treated as described below to isolate AML cells.  
 
2.3.3 Isolation of mononuclear cells 
A butterfly needle and 50 ml syringe was used to extract 45 ml blood from a healthy donor. 
The blood was added to 5 ml Sodium Citrate in a 50 ml Falcon tube (1:10 dilution) and 
inverted to prevent blood clotting. Blood was mixed with 50 ml of 50% Hank’s solution. 
Histopaque solution (15 ml) was added to each of four 50 ml falcon tubes. Blood mixed with 
Hank’s solution was distributed evenly between the four Falcon tubes (25 ml in each): blood 
was carefully and slowly added to the tubes which were held at an angle to ensure there was 
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no mixing of blood into the Histopaque solution. Blood was spun in a centrifuge at 1800 rpm 
(402 rcf) for 20 min with the brake of. After spinning, the layer of monocytes that formed in 
the tube were removed by pipetting and transferred to a new 50 ml falcon tube. Cells were 
spun at 1500 rpm for 10 min then supernatant was removed. Cells were re-suspended in 50 
ml Hank’s solution. At this point, 20 µl of cells were taken for a cell count. Cells were spun 
again in the 50 ml falcon tube at 200 g, supernatant was removed, cells were re-suspended 
in 50 ml Hank’s solution and spun again at 200xg. Supernatant was removed and cells were 
re-suspended in 300 µl of buffer for magnetic labelling. Buffer was made up of 0.5% Bovine-
Serum Albumin, 2mM EDTA and PBS pH 7.2. 
 
2.3.4 CD34+ cell magnetic labelling and separation 
Throughout the process, cells were kept cool and pre-cooled solutions were used. The 
volumes for magnetic labelling were for up to 108 total cells, when there were fewer or higher 
cell numbers, volumes were scaled down or up accordingly. To the 300 µl of cells in buffer, 
100 µl of FcR blocking reagent was added, followed by 100 µl of CD34 MicroBeads. This 
was mixed well and refrigerated for 30 min (4-8 ˚C). Cells were washed by adding 5-10 ml of 
buffer and centrifuged at 300xg for 10 min. Supernatant was completely removed and cells 
were re-suspended in 500 µl of buffer.  
 
MACS separation column (size MS) was placed in the magnetic field of a suitable MACS 
Separator. MS Columns were prepared by rinsing with 500 µl of buffer. Cell suspension was 
added to the column. Unlabelled cells that passed through the column were collected and 
the column was washed with 500 µl of buffer three times. New buffer was only added when 
the column reservoir was empty. The column was removed from the separator and placed 
on 15 ml falcon tube for collection of cells. One ml of buffer was pipetted onto the column 
and magnetically labelled cells were flushed out immediately by firmly pushing the plunger 
into the column. CD34+ cells were collected in an eppendorf tube.  
 
2.3.5 RNA extraction 
Cells suspended in media were added to an eppendorf tube and spun at 13000rpm for 2 min 
to create a cell pellet. Supernatant was removed by pipetting. Cells were re-suspended in 
nucleic acid purification lysis solution (Applied Biosystems). RNA was extracted using the 
ABI Prism 6100 Nucleic Acid PrepStation set to RNA cell method. RNA was collected in Bio 
Rad individual PCR tubes and stored at -20˚C unless immediately used.  
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2.3.6 Reverse Transcription 
Master mix containing random hexamers (Quiagen), MgCl2, 10x reverse transcription buffer, 
dNTPs, Reverse Transcriptase and RNAse (all Applied Biosystems) was made up and 6 µl 
of this was added to 4 µl of RNA. PCR tubes containing master mix and RNA were put into 
the C1000 Bio Rad Thermal Cycler machine and set to 42˚C for 15 min, 95˚C for 3 min then 
cooled to 4˚C. Once the reaction had stopped, tubes were removed from the Thermal Cycler 
and 90 µl of double distilled water was added to each sample of cDNA.  
 
2.3.7 Real- time PCR 
cDNA samples were taken and 5 µl from each was added to an individual well in the 96 well 
PCR plate. Master mix was made up from SYBR green (Roche), relevant primers (Primers 
(Invitrogen) diluted at 15 µl forward primer+15 µl reverse primer and 270 µl double distilled 
water) and double distilled water. Of this master mix, 15 µl was added to each well of the 
PCR plate already containing cDNA. The 96 well plate was inserted into the Light Cycler 480 
qRT PCR machine (Roche) and programmed to run for 55 amplification cycles and to 
measure the melting curves for each sample.  
 
2.3.8 Immunostaining and image acquisition  
Cell samples used for immunostaining included HL60 and THP1 cell lines and various AML 
patient samples. Cells were suspended in media and 150μl of this was added for each 
sample in a Shandon Double Cytofunnel (Thermo Scientific). Cell samples were spun onto 
glass Poly Prep slides (Sigma-Aldrich) in a Cytospin 4 machine (Thermo Shandon) set to 
500rpm for 5 min. A ring was drawn around each cell sample using a liquid repellent slide 
marker pen. Cells were fixed in 4% paraformaldehyde, pH 7.4 for 15 min. Cells were washed 
in PBS: PBS was added, left to wash for 5 min, removed by pipetting and then repeated 
once. Cells were blocked for 15 min using 30% goat quench (in 50 ml: 15 ml goat serum 
30%, 35 ml gelatine quench buffer). Goat quench was removed by pipetting and cells were 
permeabilised for 20 min in 0.5% Triton X-100 in 30% goat quench. Permeablisation solution 
was removed and cells were incubated for 1 hour at 4˚C in primary antibody. Antibodies 
were diluted to 0.5 μl in 1000 μl 30% goat quench. Cells were washed in PBS for 5 min three 
times then incubated at 4˚C in secondary antibody for 40 min. Cells were washed in PBS for 
5 min three times. DAPI was added to the cells at a concentration of 1 in 2000 and left for 20 
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min. DAPI was removed and cells were mounted in Fluoromount G and cover slips were 
added. Stained slides were stored at 4˚C.  
 
Slides were viewed and images were acquired using a Zeiss AxioCam MRm fluorescent 
microscope. 
 
2.3.9 Anti-TNF treatment  
A stock solution of anti-TNF was diluted using double distilled water to the required 
concentration of 3 μg/ml and added to HL60, U937, and THP1 cells plated at 1x105 cells per 
well in 12 well plates. Each well contained 2 ml of media. Other wells containing the cell lines 
were also left as controls – no anti-TNF was added. Cells were incubated for the required 
time periods (0, 4, 8, 24, 48 or 72 hours) following the anti-TNF treatment.  
 
2.3.10 MTS assays 
Following the appropriate incubation periods, a sample of cells were taken from their plates 
by pipetting. Cells were transferred into MTS plates with 100 μl of cells in each well. 15 μL of 
MTS was added to each well of the MTS plate containing a cell sample. Cells were 
incubated with MTS for 45 min then cell death was measured using a BMG Labtech MTS 
plate reader.  
 
2.3.11 Protein extraction 
Cells required for protein analysis were spun at 13000 rpm for 10 seconds. Once a pellet 
had formed, the supernatant was removed and the pellet re-suspended in 40 μl of cell lysate 
(mixed by pipetting the solution repeatedly up and down).  
 
2.3.12 Western blotting 
Resolving gel (12%) was made containing distilled water, 30% acrylamide mix, 1.5M TRIS 
(pH 8.8), 10% Sodium Dodecyl Sulphate (Melford), 10% ammonium persulphate and 
TEMED. Resolving gel was pipetted between two glass plates and left to set. A few drops of 
butanol were added to the top of the gel to level it out and remove bubbles. Stacker gel was 
made using distilled water, 30% acrylamide mix, 1.0M TRIS (pH 6.8), 10% SDS, 10% 
ammonium persulphate and TEMED. Stacker gel was added to the top of the glass plates on 
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top of the resolving gel. A comb was added to create the wells, each tooth of the comb had a 
width of 4 mm.  
 
Once the gels are set, the lane combs and the glass plates were removed from their holders 
and transferred into an electrophoresis tank into which enough running buffer was added to 
cover the glass plates containing the gel. Running buffer was made up of 30g glycine (Fisher 
Scientific), 6g TRIS Base Ultra Pure (Formedium), 24 ml 10% SDS and 2 l of distilled water. 
Buffer was pipetted in and out of each well to clean it. From each protein sample, 20-40 µl 
was carefully pipetted into each well with a DNA ladder in one of the end wells. The gel was 
run for 40 min at 200V.  
 
Membranes were activated in methanol for 10 seconds then washed three times with 
distilled water and placed in transfer buffer until needed. Membranes were also marked on 
the side to face the gel. Transfer buffer was made up from 30g glycine, 6g TRIS and 2l of 
water. Once the gel was stopped, buffer was removed and the tank and gel were washed 
with distilled water. Gel was removed from the glass plates and transferred onto the cassette 
in the order: cassette black outer casing, fibre pad, filter paper, gel, activated membrane, 
filter paper, fibre pad, red cassette outer casing. All components were pre-soaked in transfer 
buffer. Before locking the cassette closed, bubbles were removed from between the gel and 
the membrane by rolling a tube across the fibre pad. The cassette was put into the transfer 
tank in the correct orientation along with a cooling unit of ice. The tank was filled with the 
correct amount of transfer buffer according to the amount of cassettes in the tank then run at 
100V for 1hour.  
 
Cassettes and membranes were removed, then membranes were blocked with milk (2.5 g 
milk powder (Marvel), 50 ml 1xPBS) for 1hour whilst rocking. Membranes were washed in 
PBS with 0.1% TWEEN three times for 10 min each time. Membranes were incubated in 
primary antibody (IkBa in 1 in 1000 dilution in milk) overnight at 4˚C. Membranes were 
washed four times for 10min each time with PBS and 0.1% TWEEN then secondary 
antibody was added (Rabbit pAb to Mouse IgG (HRP) Abcam) for an hour.  
 
Following the washing of the secondary antibody from the membranes, activator reagents 
were added to the membranes. Reagent A: 68 mM p-coumaric acid – 5 g in DMSO (22.3 mg 
in 2 ml). Reagent B: 1.25 mM luminol – 1g in 0.1M TRIS pH8.5 (44.3 mg in 200 ml). Five 
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millilitres of Reagent B and 50 µl of Reagent A were added to the membranes along with 1.5 
µl of H2O2 (30%).  
Blots were visualised using x ray film.  
 
2.3.13 Drug treatment 
Cells were plated at 1x105 cells per well in 12 well plates. Cytarabine was added to the cells 
at the necessary time periods at concentrations of 0.5 μM and 1 μM. A set of cells were left 
as controls with no cytarabine added. Daunorubicin was added to cells at 0.2 μM and 0.3 μM 
concentrations. Cells were analysed for cell death using MTS assay as described above.  
The table below lists the sequences specific to each primer used for real time PCR.  
Primer Sequence (5’ to 3’) 
NIK Forward  CCC AGG CTG AGT GTG AGA AT 
NIK Reverse  CGG ACT GGC TGT ACT GTT TG 
p65 Forward GGC GAG AGG AGC ACA GAT AC 
p65 Reverse CCT GGT CCT GTG TAG CCA TT 
p100  Forward ACA GAT GGC CCA TAC CTT CA 
p100 Reverse GAT AGG TCT TTC GGC CCT TC 
p105 Forward ACA GAT GGC CCA TAC CTT CA 
p105 Reverse AGG TAG TCC ACC ATG GGA TG 
cRel Forward TCC ATT CAA TGT CCC TGA AA 
cRel Reverse CCA TGT TCA TCA GGG AGA AAA 
IκBα Forward GAG CCC TGG AAG CAG CAG 
IκBα Reverse CTC CGC CAC TTA CGA GTC C 
RelB Forward CTT ACG GAG GCC GAG CAG 
RelB Reverse TTC AGT TCT TTG GCC TCT TG 
 
Table 1: Sequences specific to each primer used for real time PCR.  
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Chapter 3: Expression levels of NF-κB signalling 
molecules in human AML 
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3.1 Introduction 
In the majority of cell types, NF-κB is found in the cytoplasm in its inactive form. Upon 
stimulation from factors such as TNF, the inhibition of NF-κB signalling is lost, and so begins 
the cascade of signalling events which lead to the nuclear translocation of NF-κB. Once in 
the nucleus, NF-κB forms an active transcriptional complex with DNA encoding 
inflammatory, pro-apoptotic and anti-apoptotic genes (Zhou et al 2003) 
 
3.1.1 NF-κB in AML 
In unstimulated primary AML cells, studies have detected aberrant NF-κB activity (Monica et 
al 2001). NF-κB signalling provides cells with antiapoptotic activity and is therefore 
considered to be an important survival factor for AML cells. Because NF-κB has a major role 
in mediating cell survival, it has become a target for cancer therapy (Wang et al 1996). 
Treating healthy monocytes or macrophages with TNF in physiologic conditions does not 
induce cell death because the NF-κB signalling pathway becomes activated and triggers the 
expression of antiapoptotic genes (Want et al 1998). Cell death will only occur in such cells 
when NF-κB signalling is inhibited (Liu et al 2004). NF-κB inhibited AML cells do not however 
respond in the same way to TNF treatment and apoptosis does not occur (Rushworth and 
MacEwan 2008). 
 
NF-κB signalling components have been investigated and the following results gathered 
because of the constitutive activation of NF-κB in monocytes of AML patients (Guzman et al 
2001) and its great influence on the survival of such cells. 
 
3.2 mRNA expression of canonical NF-κB subunits in AML 
Components of the canonical and non-canonical NFκB signalling pathway were investigated 
in healthy CD34+ cells, AML cell lines (HL60, U937 and THP1), and AML cell patient 
samples to compare their mRNA levels. The aim of this was to discover whether their levels 
of mRNA were increased, decreased or remained the same in AML compared to healthy 
CD34+ cells. The result of this investigation hoped to give a clearer idea of any effect a 
change of expression could have on the NFκB signalling pathway and ultimately, the final 
signalling outcome and fate of the cell. 
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p105 mRNA expression. 
A Student’s T-test was performed on the data for p105 (Figure 1A), comparing the control 
CD34+ cells to all of the AML cell samples. The result was 0.852 (to three significant figures) 
which shows that there is no significant difference between the CD34+ cells and the AML 
patient samples collectively. 
 
When the results are viewed more closely however, the majority of the results for AML 
samples are below 0.5 besides AML samples 103, 212 and 314 in particular. So with these 
three results removed and the T-test is re-calculated, the result is 0.00632 which shows that 
there is a significant difference in mRNA levels of p105 between the majority of AML 
samples and the CD34+ cell samples. 
 
A further T-test was carried out on the data for the cell lines’ mRNA levels for p105 
compared with those of the AML patient samples. This test was performed to determine 
whether the mRNA data for the cell lines was representative for that of actual AML patient 
samples. The result of the T-test was 0.613 which shows that there was no significant 
difference between the data for the AML cell lines and for that of the AML patient samples. 
This confirms that the data collected from the AML cell lines was indeed representative of 
data from AML cell samples. 
 
p65 mRNA expression.  
A Student’s T-test was performed on the data for p65 (Figure 1B), comparing the control 
CD34+ cells to all of the AML cell samples. The result was 0.519 which shows there is no 
significant difference in mRNA levels between CD34+ cells and AML patient samples. 
However, much like the results for p105, the levels of p65 in AML samples 103, 212 and 314 
are particularly elevated. So a separate T-test was performed for the p65 results without the 
above three AML samples to see if this made a difference. The second T-test result was 
0.923 which strengthens the hypothesis that there is no significant difference in p65 mRNA 
levels whether they are measured in AML or healthy CD34+ cells. 
 
Once again, a further T-test was carried out to compare the mRNA levels for p65 in AML cell 
lines and AML cell samples. The result of the T-test was 0.660 which meant there was no 
significant difference between the two sets of results. This means that using HL60, U937 and 
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THP1 cell lines to measure cellular p65 mRNA levels would generally be indicative of the 
same mRNA levels in AML patient samples. 
 
cRel mRNA expression. 
 A Student’s T-test was performed on the data for cRel (Figure 1C), comparing the control 
CD34+ cells to all of the AML cell samples. The result was 0.365 which shows that there is 
no significant difference in cRel levels between the CD34+ control cells and the AML cell 
samples. Therefore these results show that cRel mRNA levels are neither reduced nor 
increased generally in AML. On the other hand, these results do show that there is a great 
deal of variation in cRel mRNA levels between patients with AML. 
 
A T-test was performed on the cRel mRNA results from the AML cell lines and AML cell 
patient samples. The result was 0.169, meaning there was no significant difference between 
the two sets of results, which leads to the conclusion that the AML cell lines may be used to 
determine cRel mRNA levels in AML. 
 
IκBα mRNA expression.  
A Student’s T-test was performed on the data for IκBα (Figure 1D), comparing the control 
CD34+ cells to all of the AML cell samples. The result was 0.00000840 concluding that there 
is a significant amount of difference in IκBα levels between CD34+ cells and AML samples. 
IκBα levels are significantly reduced in AML cells when compared with healthy CD34+ cells. 
A T-test was also performed to compare the AML cell line data with that of the AML cell 
patient samples. The result of this test was 0.696 which gives the conclusion that there is no 
significant difference between the two sets of data, again leading to the notion that AML cell 
lines are behaving in the same way as AML cell patient samples.  
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 3.3 mRNA expression of non-canonical NF-κB subunits in AML 
RelB mRNA expression. 
A Student’s T-test was performed on the data for RelB (Figure 2A), comparing the control 
CD34+ cells to all of the AML cell samples. The result was 0.0000264 which shows that 
there is a significant difference between the sets of data for RelB mRNA levels in CD34+ 
cells and AML cell patient samples. mRNA levels for RelB are significantly reduced in AML 
cell samples when compared to those of healthy CD34+ cell samples. 
 
A separate T-test was performed on the data for RelB to compare mRNA levels between the 
AML cell lines and AML cell samples. The result of this test was 0.984 which shows there is 
no significant difference between the two sets of data. This lack of difference shows that in 
the case of RelB mRNA levels, AML cell lines and AML cell samples are very similar. 
 
p100 mRNA expression.  
A Student’s T-test was performed on the data for p100 (Figure 2B) to compare mRNA levels 
of the control CD34+ cells to those of all the AML cell samples. The result was 0.478 which 
shows there was no significant difference between the two sets of data. Even with the high 
levels of p100 mRNA recorded for AML samples 310, 311, 312, 314, 316 and 317 removed 
from the T-test, the result is still 0.184 which brings about the same conclusion. Therefore 
from these results, it appears that p100 mRNA levels remain unchanged when healthy cells 
transform into leukaemic AML cells. 
 
Another T-test was performed to compare the p100 mRNA levels for the AML cell lines and 
the AML cell patient samples. The result was 0.703 which means there is no significant 
difference between the two sets of data. This means that mRNA levels of p100 in cell lines 
closely resembles those of AML cell patient samples. 
 
NIK mRNA expression.  
A Student’s T-test was performed on the data for NIK (Figure 2C) to compare mRNA levels 
of the control CD34+ cells to those of all the AML cell samples. The result was 0.0653 which 
shows there is no significant difference between the CD34+ cells and the AML cell patient 
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samples. This suggests that there is no difference in mRNA levels of NIK between healthy 
CD34+ cells and leukaemic AML cells. 
 
As the results are viewed in the form of a graph, it does however appear that NIK mRNA 
levels are generally a little lowered in AML cell patient samples. If, like for the results of p100 
mRNA AML samples; 310, 311, 312, 314, 316 and 317 are removed and the T-test is 
repeated, the result becomes 0.0102 which does show a significant difference between the 
two sets of data. This would suggest that there may be a significant decrease in NIK mRNA 
levels in AML cell patient samples compared to healthy CD34+ cells, however the results for 
those six AML cell samples shall not be disregarded. 
 
Another T-test was carried out to compare the data for mRNA levels of NIK in AML cell lines 
and the AML cell samples. The result was 0.0675 which shows there is no significant 
difference between the two sets of data. This suggests that NIK mRNA levels in AML cell 
lines HL60, U937 and THP1 are indicative of those in leukaemic cells in AML patients. 
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3.4 Protein expression of canonical NF-κB subunits in AML 
Much like the investigation for mRNA expression levels of both canonical and non-canonical 
NFκB signalling pathways in AML, protein expression was also analysed.  
 
It is generally thought that mRNA expression levels closely reflect expression levels of the 
proteins for which they code for. Some studies however have shown moderate and varied 
correlations between the two (Guo et al 2008), which suggests that mRNA expression may 
sometimes be a useful tool in predicting protein expression levels but it should not be 
regarded as an exact representation. 
 
Expression levels of the proteins p50, p65, IκBα, RelB, p100 and NIK were investigated in a 
representative number of AML cell patient samples. The aim of this was to discover where in 
the cell the proteins were being expressed in AML cells.  
 
p50 protein expression. 
It appears from the set of images for p50 in Figure 3 that there is more p50 protein 
expression in the cytoplasm of the AML patient’s cell than there is in the nucleus. The 
fluorescent staining showing the presence of the p50 protein within the cell is a lot more 
intense in the periphery of the cell as opposed to the area within the nucleus (defined by the 
DAPI staining). There does appear to be some p50 present in the nucleus which suggests 
that the p50 subunit is also in the nucleus of AML samples.  
 
p65 protein expression. 
The image in Figure 3 representing p65 protein expression shows low levels of p65 within 
the nucleus of the AML patient cell and higher levels within the cytoplasm at the periphery of 
the cell. As with p50, there does appear to be some p65 protein to be found within the 
nucleus but as the intensity of the staining is much lower than in the cytoplasm. However it 
does imply p65 activity in these AML cells.  
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IκBα protein expression  
Protein expression of IκBα within the two AML patient cell samples shown in Figure 3 
appears to occur mainly within the cytoplasm of the cells. There does appear to be some 
IκBα expression in the nucleus of the cell but at a lower level than in the cytoplasm. 
 
3.5 Protein expression of non-canonical NF-κB subunits in AML 
RelB protein expression  
Expression of RelB protein in the AML patient sample shown in Figure 4 clearly appears 
much greater in the cell’s cytoplasm than in the nucleus. There is a definite area in the top 
image (RelB antibody alone) with very low RelB expression which exactly matches the area 
marked by DAPI staining as the nucleus. RelB staining is distinct from the DAPI staining 
which indicates that RelB is not found present in the nucleus.  
 
p100 protein expression 
The image in Figure 4 showing p100 protein expression within a cell taken from an AML 
patient’s blood sample shows more p100 protein expression in the cell cytoplasm than in the 
nucleus. The intensity of the p100 protein expression is a lot greater in the cytoplasm of the 
cell compared to the nucleus. 
 
NIK protein expression  
Expression of NIK protein is shown in Figure 4 in four cells from an AML patient sample. 
Each cell has an area, represented as the nucleus by DAPI staining, with reduced NIK 
protein expression. There does appear to be some NIK staining present within the nuclear 
area which is unexpected as NIK is only required in the cytoplasm. 
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3.6 Discussion 
T-tests carried out to compare mRNA levels for AML cell lines and actual AML cell patient 
samples showed that there was no significant difference between the two sets of data for 
any of the NFκB signalling pathway components. This gives the implication that cell lines 
may be used to decipher certain aspects of cellular activity within cells of patients with AML. 
From the results gathered here, this generally appears to be a safe assumption. What these 
results also show however is the large amount of variability between individuals with AML. 
Therefore cell lines may be used to give an insight to suggest what may be occurring within 
AML cells, but may not provide hard evidence from which to draw final conclusions. 
 
Protein expression of NF-κB subunits from the canonical and non-canonical NF-κB signalling 
pathways were investigated by immunofluorescence using cell samples from AML patients 
to discover where the proteins were being expressed. There was also a question as to 
whether or not the mRNA results for the signalling components correlated with the protein 
expression results. 
 
p105  
p105 is the precursor to the mature NF-κB subunit p50. The p50 subunit is generated by 
proteolytic processing of the 105 kDA precursor protein – the protein is ubiquitinylated then 
processed in the 20 S proteasome (Sears et al 1998). Results for mRNA levels of the p105 
subunit showed that it was slightly decreased in AML when compared to normal CD34+ 
cells. If less p105 mRNA is being transcribed then there will be less translation of the mRNA 
into p105 protein. Less p105 protein available for processing will mean that there will be less 
p50 protein present in AML cells. If there is less p50 in AML cells then less p50:p65 dimers 
will form, for translocation into the nucleus. This ties in well with the immunofluorescence 
protein staining for p50 showing reduced amounts of it in the nucleus compared with in the 
cytoplasm. There is less p50 protein in the nucleus of AML cells because there is less of it 
available to produce dimers for nuclear translocation. 
 
p65 
Protein expression of p65 was also low in the nucleus of AML cells. mRNA levels of p65 did 
not however decrease when measured in AML samples. Low nuclear p65 protein expression 
could therefore be due to the reduced amounts of p50 protein. It is necessary that p65 forms 
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dimers with p50 to be able to translocate to the nucleus so if there is less p50 available then 
less p65 will reach the nucleus. 
 
cRel 
The above reasoning for low p65 nuclear protein expression could also be applied to cRel as 
the results for cRel were very similar to those of p65. mRNA levels for cRel were unchanged 
in AML when compared with healthy CD34+ cells and cRel protein expression in the nucleus 
of AML cells was low. The low protein expression of cRel in the nucleus of AML cells may be 
due to reduced amounts of p50 available to dimerise with it in the cytoplasm. 
 
IκBα  
Protein expression of IκBα was present both in the nucleus and in the cytoplasm of the AML 
patient sample cells. The amount of IκBα in the cytoplasm was higher than in the nucleus 
and there is a definite difference in the levels of expression in the area marked as the 
nucleus by the DAPI staining. IκBα is required in the nucleus upon cell activation to 
dissociate NF-κB from the DNA and transport it back into the cytoplasm to prevent further 
DNA transcription (Prigent et al 2000). Therefore IκBα protein expression is expected in the 
nucleus when cells have been stimulated for NF-κB signalling. In unstimulated cells, IκBα 
protein expression is maintained in the nucleus but at a low level. This is to ensure that once 
cells become activated, NF-κB will have the ability to become transcriptionally active as the 
activity of NF-κB will not be inhibited by too much IκBα present (Huang et al 2000). 
 
The main result gained from these investigations is the significant amount of difference in 
IκBα mRNA levels between CD34+ cells and AML cell samples. IκBα mRNA levels were 
significantly reduced in AML cells compared to healthy CD34+ cells. This low level of IκBα 
mRNA present in AML cells is likely to translate into low levels of IκBα protein being present 
in AML cells.  As IκBα plays an important regulatory role in the NF-κB signalling pathway, 
cells with less available IκBα protein are likely to experience downstream effects.  
 
What events could be occurring upstream of IκBα to cause reduced levels of mRNA for this 
NF-κB inhibitor?  A quicker turnover of IκBα mRNA could be reducing the length of time any 
one IκBα protein is present within a cell therefore causing an overall reduction of IκBα 
present in the cell. Epigenetic changes in regulation could be occurring such as the effects of 
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miRNA or RNA methylation. Finally, inhibition of transcription could be the reason for 
decreased levels of mRNA present in AML cells in this study.  
 
RelB 
AML patient samples showed a significant decrease in mRNA levels of RelB which implies 
that there would also be low RelB protein expression. When the protein expression of RelB 
was detected, it was mainly found present in the cytoplasm of the cell. Lower levels of RelB 
protein in the cell could mean less RelB translocation from the cytoplasm to the nucleus, 
which would explain the lack of RelB in the nucleus of AML cells. 
 
p100 
The mRNA levels for p100 showed no change in AML samples when compared to healthy 
CD34+ cells however the protein expression for p100 was low in the nucleus of AML cells. 
p100 is the precursor protein to the mature p52 NF-κB subunit which is the molecule which 
translocates into the nucleus therefore p100’s presence within the nucleus would not be 
expected. 
 
NIK 
The role of NIK in the non-canonical NF-κB signalling pathway is to induce p100 processing 
via IκK molecules. This process occurs in the cytoplasm of cells therefore NIK protein 
expression should also be found in the cell cytoplasm. The images showing NIK protein 
expression do indeed show higher amounts of NIK present in the AML cell’s cytoplasm than 
in the nucleus. 
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Chapter 4:Understanding the mechanisms 
controlling the low expression of IκBα in AML 
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4.1 introduction 
The main finding from the results in chapter 3 was the low expression of IκBα mRNA in AML 
patient samples compared to control cells. Because the NF-κB signalling pathway has such 
a central role in controlling cell death, it is important to investigate what may be causing the 
low expression of IκBα and ultimately aberrant NF-κB signalling in AML.  
 
4.1.1 TNF and NF-κB in AML 
Levels of TNF are known to be elevated in AML. TNF is a cytokine that can trigger NF-κB 
signalling through the TNF receptors present on the cell membrane. AML cells also have 
higher basal levels of NF-κB signalling than healthy cells. IκBα is the inhibitor of NF-κB 
signalling therefore IκBα must be degraded in order to enable NF-κB signalling to occur. The 
elevated levels of TNF present in AML cells could be causing the low expression of IκBα 
becauseTNF signalling via NF-κB requires low levels of IκBα present in the cell. Therefore, 
the effect of TNF on IκBα will be investigated by removing TNF from AML cell lines to 
discover what happens in relation to IκBα when TNF is no longer present. 
 
4.2 Treating AML cells with anti-TNF: the effect on IκBα mRNA 
and protein 
4.2.1 IκBα mRNA levels following anti-TNF treatment 
To investigate the effect of TNF of the expression of IκBα mRNA, AML cell lines were 
treated with anti-TNF then their IκBα mRNA levels were measured by qRT PCR. The same 
cell lines were also left untreated and used as controls to compare their IκBα mRNA levels 
with the ones that had been treated. 
HL60 cells  
HL60 cells were treated with anti-TNF then left to incubate for 24 and 48 hours. Following 
these time periods, cells were taken and analysed by qRT PCR to measure their IκBα 
mRNA levels. Figure 5A shows the results from this investigation. In HL60 cells, the levels of 
IκBα in the cells incubated for 24 hours have fallen. They decrease further when cells are 
analysed at 48 hours. The IκBα mRNA levels in the HL60 cells treated with anti-TNF have 
fallen to levels lower than in the untreated HL60 cells. 
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THP-1 cells  
THP-1 cells were treated in the same way as the HL60s. Figure 5B shows after 24 hours 
following anti-TNF treatment, IκBα mRNA levels have increased slightly above the levels of 
IκBα mRNA in the control THP-1 cells after 24 hours. By 48 hours, the IκBα mRNA levels 
have almost doubled in comparison to the control cells. 
 
U937 cells 
U937 cells that were treated with anti-TNF have a much higher amount of IκBα mRNA 
present in their cells 24 hours following treatment than the control cells (Figure 5C). The 
amount of mRNA present in the treated U937s has more than doubled by 24 hours after 
treatment. U937 cells left to incubate for 48 hours following anti-TNF treatment have 
increased levels of IκBα mRNA compared to the control, but the levels are lower than those 
measured at 24 hours. 
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4.2.2 IκBα protein levels following anti-TNF treatment 
A similar investigation into the effect of treating AML cell lines with anti-TNF was carried out 
again, but this time measurements of IκBα protein were taken at 0, 4, 8, 24 and 48 hour time 
points following the anti-TNF treatment, and cells taken from the same samples were also 
used for IκBα protein analysis. 
 
Figure 6 shows the western blots from the measurements of IκBα protein levels in AML cell 
lines after treatment with anti-TNF. Figure 7 shows these same results following 
quantification by measuring the intensity of individual bands. All the levels of IκBα protein in 
figure 7 are calculated as a fold of what they were at time 0, when no anti-TNF has been 
added. Four hours following anti-TNF addition shows an increase in IκBα protein in HL60, 
THP-1 and U937 cell lines. By the 8 hour time point, protein levels for IκBα have continued 
to rise in HL60 and U937 cells. In THP-1 cells however, the protein levels have decreased 
again, but are still higher than before anti-TNF treatment. By 24 hours, all cell lines have 
lower IκBα protein levels than when they were at their peak; either at 8 hours for HL60s and 
U937s, or at 4 hours for the THP-1 cells. Despite the decrease in IκBα protein levels, they 
are still all higher than they were previous to anti-TNF treatment. 
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4.3 Effect of anti-TNF treatment on AML cell survival 
AML cell lines HL60, THP1 and U937 were treated with varying amounts of anti-TNF to 
discover the effect this had on cell death. The treated cells were compared with cells that 
had received no anti-TNF treatment. Cell death was measured with an MTS assay. 
 
HL60 cells.  
Treating HL60 cells with 1 ng/ml of anti-TNF induced cell death (Figure 8A). It can be 
concluded that the cell death occurred as a result of the anti-TNF treatment because the 
results were calculated as a fold of the amount of cell death for HL60 cells to which no anti-
TNF was added. This factors out cell death that may have occurred as a result of non-
optimal cell conditions. Cell death was measured in the same cell samples over periods of 
24 and 48 hours. More cell death occurred in HL60 cells that were treated with 1 ng of anti-
TNF for 48 hours. 
 
69 
 
THP-1 cells  
THP-1 cells were treated with 1 ng of anti-TNF for time periods of 24, 48 and 72 hours and 
the levels of cell death were measured. Figure 8B clearly shows a neat trend in the increase 
of cell death over the increasing time periods following anti-TNF treatment. By 24 hours 
following anti-TNF treatment, cell death has increased to levels above the amount of cell 
death of the untreated cells. At 48 hours, cell death has increased further and MTS readings 
of cell death showed that the highest amount was occurring once cells had been treated with 
anti-TNF then incubated for 72 hours. 
 
U937 cells  
U937 cells were treated with 1 ng of anti-TNF then left to incubate for 24, 48 and 72 hours 
(Figure 8C). Cell death is increased following anti-TNF treatment in U937 cells after 24 
hours. Cell death appears to decrease after 48 hours as the results show an increase in the 
number of cells present in the sample on the MTS plate, however this is most likely to be an 
anomalous result possibly caused by bubbles in the cell solution causing an obstruction to 
the MTS plate reading. U937 cells were treated with a higher amount of 3 ng of anti-TNF 
which caused more cell death to occur after 24 hours than when cells were treated with 1 ng 
of anti-TNF. Cell death increased even further once cells had been incubated for 48 hours 
with 3 ng of anti-TNF. 
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4.4 Effect of anti-TNF and drug treatment on AML cell survival 
Chemotherapeutic drugs such as Daunorubicin and Cytarabine are established drug 
treatments for AML (Feldman et al 2008). They both affect cell’s DNA which disrupts the cell 
cycle which leads to cell death. These chemotherapeutic drugs were used in combination 
with TNF to investigate their combined effect on cell death of AML cell lines HL60, U937 and 
THP-1. Each cell line was treated with anti-TNF, Daunorubicin, Cytarabine, Daunorubicin 
with anti-TNF, Cytarabine with anti-TNF and two samples left with no treatment as controls. 
Cells were left to incubate for 24 and 48 hours to see the effect of the treatments on cell 
death over time. 
 
HL60 cells.  
Treatment with anti-TNF alone causes a small amount of cell death as demonstrated 
previously by the results in figure 8A. Once again, the levels of cell death in HL60 cells 
treated with anti-TNF are higher than those of the control cells (Fig 9A), meaning that the cell 
death that has occurred is as a result of the anti-TNF treatment. 
 
Treating HL60 cells with both types of drug produces a more dramatic effect on the increase 
of cell death than treating with anti-TNF alone. Daunorubicin appears to have a slightly 
greater effect on cell death than Cytarabine does. It is clear that increasing the dosage of 
Daunorubicin also increases the amount of cell death after 24 hours however this effect 
becomes less obvious after 48 hours. The same effect is not obvious with increasing the 
dosage of Cytarabine. 
 
A T-test was performed to compare the data collected after 24 and 48 hours. The result was 
0.000765 which shows that there is a significant difference between the two sets of data. In 
this case, that means there was a significant increase in cell death when cells were left to 
incubate for 48 hours following treatment rather than just 24 hours. 
 
 
THP-1 cells.  
Treatment of THP-1 cells with anti-TNF alone in the previous experiment (figure 8B) clearly 
showed cell death as a result of this treatment. Such an effect in figure 9B is also obvious 
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after 48 hours but does not appear to be the case for THP-1 cells after 24 hours. Cells 
appear to have proliferated according to figure 9B however this is likely to be an anomalous 
result perhaps caused by an air bubble in the well of the MTS plate. 
 
Treating the THP-1 cells with Daunorubicin and Cytarabine has a greater effect on 
increasing cell death than when treating the cells with anti-TNF alone. An increase in dosage 
of both chemotherapeutic drugs has a positive effect on the increase of cell death, 
particularly with Daunorubicin. Treating cells with a combination of the chemotherapeutic 
drugs and anti-TNF does not appear to have any beneficial effect on causing cell death in 
THP-1 cells. 
 
A T-test was performed to compare the results after 24 and 48 hours, the result was 0.697 
which shows there was no significant difference between the two sets of results, meaning 
that there was no significant difference in the amount of cell death after 48 hours compared 
to that of 24 hours. The difference may not have been significant however studying figure 9B 
does reveal a slight overall increase in cell death. 
 
U937 cells  
U937 cells treated with anti-TNF alone after 24 hours gives an increase in cell death when 
compared to control cells that were left untreated. The result for 48 hours following anti-TNF 
treatment would suggest cell proliferation however this result could be anomalous and 
perhaps due to air bubbles present in the MTS plate well. 
 
Figure 9C shows that treating U937 cells with Daunorubicin increases cell death. Such an 
effect is increased further by increasing the dosage of Daunorubicin treatment. The same 
cannot be said however for treatment of U937 cells with Cytarabine which has appeared to 
actually have no effect on cell death. 
 
Treating U937 cells with Daunorubicin and anti-TNF together has a slight beneficial effect on 
increasing cell death after 48 hours. After 48 hours, Daunorubicin had a greater effect on 
increasing cell death in U937 cells. All of the results taken together after 48 hours however 
were not significantly different from the results taken at 24 hours proven by the result of a T-
test being 0.560. 
73 
 
 
 
 
74 
 
4.5 Discussion 
4.5.1 Effect of anti-TNF treatment on IκBα mRNA and protein levels in AML cells. 
AML cell lines HL60, U937 and THP-1 were treated with anti-TNF to investigate the effect of 
reduced TNF signalling on the levels of IκBα mRNA present within the cells. The data in 
figure 5 shows that in THP-1 and U937 cells, IκBα mRNA levels increased following anti-
TNF treatment. This result was to be expected. 
 
Previous results from investigations into IκBα mRNA levels in AML patient samples have 
shown that IκBα mRNA is reduced in AML. It is already established that AML has slightly 
increased TNF levels above those of healthy cells, which therefore lead to the notion that 
increased TNF is increasing IκBα levels and not negatively regulating IκBα.  More TNF 
present in AML cells would lead to more activation of the TNF receptors. This leads to 
activation of IκB kinase (IKK) which phosphorylates two serine residues located on the IκB 
regulatory domain. IκBα then becomes degraded in the proteasome and its inhibitory action 
against NF-κB subunits is lost.  Therefore, treating the AML cells with anti-TNF would 
prevent TNF signalling and prevent the dysregulation of IκBα, hence the increase in levels of 
IκBα mRNA following anti-TNF treatment. 
 
The results presented in figure 5 for the HL60 cells do not comply with the results for cell 
lines U937 and THP-1 and are not what was expected. Figure 7 does however show HL60 
cells with increased IκBα protein following anti-TNF treatment. The HL60 cells in this 
investigation behaved as expected and also in the same way as the other two cell lines, 
whose IκBα mRNA also increased following anti-TNF treatment. 
 
What was interesting and perhaps unexpected about the results shown in Figure 7 was that 
each cell line had a peak in IκBα protein levels either at 4 hours for THP-1 cells or at 8 hours 
for HL60s and U937s, then following that peak, IκBα protein levels decreased again but not 
to below the original levels before anti-TNF treatment. 
 
4.5.2 Effect of anti-TNF treatment on AML cell survival. 
All the AML cell lines used in the investigations into the effect of anti-TNF on cell death 
showed increased cell death following increased amounts of anti-TNF treatment over longer 
time periods. Treating cells with 3 ng of anti-TNF had a greater effect on the amount of cell 
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death that occurred. The effect of the anti-TNF treatment became greater with time, this was 
apparent as there was more cell death in cell lines that were left to incubate for up to 72 
hours. 
 
TNF-α is known to inhibit induce apoptosis in differentiated cells (Chaudhary et al 1997). On 
the other hand, for early haematopoietic precursors, TNF-α provides survival signals to the 
cells (Gersuk et al 1998). AML is known to have high levels of TNF which is why 
investigations were made into the effects of removing TNF from the AML cell lines by 
addition of anti-TNF. Removal of the TNF signalling in AML cell lines also removes the 
survival signals from the cells, thus causing more cell death. This is reflected in the results 
shown in figure 8. 
 
4.5.3 Effect of anti-TNF and drug treatment on AML cell survival. 
Figure 9 shows all the results from the investigations into treating AML cell lines (HL60, 
U937 and THP-1) with combinations of anti-TNF and with the chemotherapeutic drugs 
Daunorubicin and Cytarabine. The results show that HL60 cells generally show better 
responses to anti-TNF and drug treatments, with more increases in cell death than with the 
other two cell lines. There was also a significant increase in cell death of HL60s 48 hours 
following treatment. The results also collectively show that Daunorubicin had a greater effect 
on cell death of all cell lines than Cytarabine did. 
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Chapter 5: Discussion 
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5.1 Summary 
This study investigated the mRNA expression of NF-κB signalling components in AML. The 
main results showed that IκBα and RelB levels were found to be significantly reduced in 
AML cells compared to healthy CD34+ cells. This lead to further investigation into the 
expression of IκBα in AML. Basal levels of TNF are higher in AML cells (Bueso-Ramos et al 
2004; Rushworth et al 2010), which is likely to have a poitive effect on the amount o f IκBα 
present in AML cells as TNF induces IκBα expression through feedback by NF-κB.  This 
effect was investigated by measuring the expression levels of IκBα following treatment of 
AML cell lines with anti-TNF.  IκBα mRNA and protein expression showed a significant 
increase as a result of anti-TNF treatment, suggesting a different mechanism is regulating 
IκBα expression in human AML. Cell death was also investigated in AML cell lines treated 
with anti-TNF. There was more cell death in cells following anti-TNF treatment than in cells 
left alone. This investigation provides novel information about NF-κB signalling components 
in AML and the effect that treating AML cells with anti-TNF has on these NF-κB proteins and 
ultimately on cell death.  
 
5.2 reduced IκBα and RelB expression in AML – 
variation in AML patients and overall effect 
IκBα and RelB expression levels were significantly reduced in AML cells. This meant that 
collectively, AML samples had significantly lower expression of IκBα and RelB compared to 
the healthy CD34+ cells. When studying the results of AML patient samples individually 
however, it becomes obvious that generalisations may not be possible due to the large 
amounts of variation of expression of NF-κB subunits between AML patients. From these 
particular results however, it has been shown that IκBα and RelB in particular have low 
levels of expression therefore it would be fair to expect the same expression patterns in 
other AML patients. It would also be reasonable to expect large amounts of variation in the 
low expression of IκBα and RelB between AML patients.  
 
Despite different AML patient samples having the same low levels of IκBα and RelB 
expression, such patients may still have completely different outcomes to each other in 
terms of response to treatment, pathology of the disease and survival. The study into mRNA 
levels of NF-κB components showed large amounts of variation for each AML patient 
sample. For example, AML sample 301 had higher levels of p105, p65, cRel, RelB, p100 
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and NIK than AML sample 185 but had similar low levels of IκBα. AML sample 307 had 
higher p105 and cRel than AML sample 301, lower RelB and NIK, and around the same 
levels of p65, IκBα and p100. Therefore, IκBα expression may be reduced in all AML 
patients however the cell’s response to NF-κB signalling will also depend on the signalling 
from all the other NF-κB components put together, both canonical and non-canonical. So 
predicting a patient’s outcome from the disease is an extremely complex matter because all 
signalling components need to be taken into account and their effects studied as one big 
picture, rather than individually. This point is demonstrated by large variations in the 
outcomes of patients even within the same FAB classification group of AML.  
 
5.3 protein expression of NIK and nuclear NIK 
Protein expression of the NF-κB subunits was studied by immunofluorescent cell staining to 
gain insight into the location of the proteins within the AML cells. NIK protein expression was 
found in the nucleus of AML cells in this study. NIK is a regulatory kinase responsible for the 
activation of non-canonical NF-κB signalling. The main role of NIK requires it to be present 
within the cytoplasm therefore it is not expected to be present in the nucleus of a cell in large 
amounts. Previous studies by Birbach et al (2004) have also found NIK in the nucleus of 
cancerous HeLa cells and have suggested a special role of nuclear NIK for an elevated 
constitutive NF-κB activity in those cells.  
 
NIK has been found to undergo nuclear-cytoplasmic shuttling in non activated cells (Birbach 
et al 2002). NIK has both nuclear localisation signals (NLS) and nuclear export signals 
(NES) which are both required for the dynamic exchange of NIK between subcellular 
compartments. The nucleus of a cell is known to be a highly dynamic organelle containing 
distinct sub-compartments (Carmo-Fonseca 2002). Such compartments are not defined by 
membranes but are however regarded as distinct compartments. Proteins may accumulate 
in such compartments by interaction with local high-affinity binding sites (Misteli, 2001). NIK 
may be held in nuclear compartments such as the nucleolus by interaction with structural 
motifs in rRNA (Birbach et al 2004).  
 
NIK may be required in the nucleus and nucleolus for many reasons. NIK activates IKK 
which itself shuttles between the cytosol and nucleus (Birbach et al 2002). IKK can 
upregulate target genes like NF-κB by binding to promoter elements, also direct 
phosphorylation of histones and facilitation of the transcription process (Anest et al 2003 and 
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Yamamoto et al 2003). NIK may also be required in the nucleus because NIK and IKK 
directly activate p65 via phosphorylation on the transactivation domain of p65 (Jiang et al 
2003). All nuclear functions of NIK and IKK may be regulated by the distribution of NIK 
between the nucleoli and nucleoplasm (Birbach et al 2004).  
 
5.4 IκBα protein expression in nucleus and IκBα protein 
shuttling 
IκBα protein was mainly found to be expressed in the cytoplasm of the AML patient sample 
cells. The majority of IκBα expression is expected in the cytoplasm of unstimulated cells 
because it is a regulatory IκB subunit that inhibits the translocation of p50 and cRel/p65 NF-
κB dimers into the nucleus. Upon IκBα phosphorylation, ubiquintation and degradation, the 
nuclear localisation signal of the NF-κB subunits becomes unmasked (Beg et al 1992) 
leaving them free to translocate to the nucleus. In stimulated cells where the NF-κB pathway 
has been activated and transcription of NF-κB genes is occurring, IκBα protein synthesis is 
stimulated so that IκBα can enter the nucleus of the cell to remove NF-κB from its gene 
promoters (Arenzana-Seisdedos et al 1995). The export of such IκBα/NF-κB complexes out 
of the nucleus and into the cytoplasm to restore the pre-stimulation state of the complexes is 
a process known as postinduction repression (Arenzana-Seisdedos et al 1997). 
 
 In HeLa and peripheral blood T-lymphocytes, IκBα is expressed not only in the cytoplasm of 
the cells but also in the nucleus in the absence of NF-κB stimulation (Huang et al 1999). 
Nuclear IκBα is maintained at low levels so that when cells are activated, NF-κB will have 
the ability to be transcriptionally active without being immediately removed from the nucleus 
by IκBα (Huang et al 1999). Huang et al have also found that the dominant nuclear export 
over nuclear import of IκBα contributes to the largely cytoplasmic localization of the inactive 
complexes to achieve efficient NF-κB activation by extracellular signals.  
 
To summarise, AML cells were found to have higher IκBα protein expression in the 
cytoplasm of the cells than in the nucleus. IκBα is expressed in the cytoplasm of the cell to 
regulate NF-κB signalling by inhibition of p50 and RelB/p65 subunits. Some IκBα expression 
was present in the nucleus because IκBα is able to remove the transcriptional activity of NF-
κB subunits by shuttling them out of the nucleus and back into the cytoplasm.  
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5.5 IκBα regulation of Rel and NF-κB family components 
Transcription factors in the Rel/NF-κB family are all related to each other over a region of 
about 300 amino acids called the Rel Homology Domain (RHD) which governs DNA binding 
and dimerisation. Each protein has a nuclear localisation signal (NLS) however the various 
homo- and heterodimers of NF-κB are maintained in the cytoplasm by IκBα which masks the 
NLSs. NF-κB proteins are free to enter the nucleus following proteasomal degradation of 
IκBα. IκBα degradation occurs following phosphorylation of two serine residues in the N-
terminal region of the molecule and consequently ubiquitination of IκBα (Brown et al 1995).  
 
The interactions between the NLSs of a Rel/NF-κB dimer and IκBα have been investigated 
by Latimer et al (1998). Their study showed that neither the RelA nor c-Rel homodimers 
require NLSs to bind to IκBα. On the other hand, their study showed that in the absence of 
an NLS in RelA or c-Rel, IκBα has a significantly reduced ability to inhibit DNA binding. Also, 
complexes of IκBα with NLS deletion mutants of RelA or c-Rel were significantly less stable 
than complexes of IκBα with the wild-type RelA or c-Rel. This therefore suggests that IκBα 
contacts one or both of the RelA or c-Rel NLSs to stabilise the interaction but this contact is 
not required for binding. 
 
 The story is different for the interactions between p50 and IκBα however, where such 
interactions do require the NLS for binding. There are certain residues present within the p50 
NLS that are required for binding with IκBα, and this depends on their charge. Finally, in a 
p50-IκBα complex or a c-Rel-IκBα complex, the N terminus of IκBα either directly or 
indirectly masks one or both of the dimer NLSs (Latimer et al 1998). This is how IκBα exerts 
its inhibition on the Rel/NF-κB dimers within the cytoplasm of cells.  
 
5.6 The IκB family  
There are three members in the IκB family and they do not all respond in the same way to 
NF-κB-inducing signals. The three members are IκBα, IκBβ and IκBε (Thompson et al 1995 
and Haskill et al 1991). The carboxyl-terminal regions of the precursors for p50 and p52, 
respectively p105 and p100 can also function as IκBs. Each family member contains six 
copies of an ankyrin repeat which functions as a protein-protein interaction domain 
(Simeonidis et al 1999). The region carboxyl-terminal to the ankyrin repeats contains a 
proline (P), glutamate (E), serine (S), and threonine (T) (PEST) sequence regulating basal 
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level protein turnover and is also required for inhibition of DNA binding whist the amino-
terminal region is the signal responsive domain (Verma et al 1995 and Ghosh et al 1998).  
 
All the IκBs share structural similarities however they exhibit substantial differences in vivo 
which depends on the cell type and on the stimulus ( Simeonidis et al 1997, Suyang et al 
1996 and Chu et al 1996). Generally, IκBα is rapidly degraded whereas IκBβ and IκBε are 
degraded more slowly (Thanos et al 1995 and Ghosh et al 1998). Also, IκBα is a stronger 
inhibitor of NF-κB than IκBβ or IκBε (Simeondis et al 1997).  
 
As previously mentioned, IκBα does not only inhibit NF-κB signalling by masking the NLSs of 
Rel/NF-κB dimers, it also enters the nucleus and can inhibit NF-κB-DNA binding. IκBs can 
promote transport of NF-κB out of the nucleus and into the cytoplasm, thus terminating 
transcription and resetting the switch (Tran et al 1997). IκBα is a stronger nuclear inhibitor of 
nuclear NF-κB activity than IκBβ and IκBε does not efficiently enter the nucleus (Arenzana-
Seisdedos et al 1995). This further demonstrates the differential inhibitory strengths of IκB 
proteins.  
 
5.7 Regulation of IκB  
5.7.1 Regulation of IκBα by IKK 
Like all inhibitors, there is a mechanism in place to regulate the activity of IκBα to allow NF-
κB signalling to occur when required. Potent NF-κB activators can induce almost complete 
degradation of IκBs, particularly IκBα, within minutes. This process, which is mediated by the 
26S proteasome (Alkalay et al 1995) depends on the phosphorylation of two conserved 
serines in the N-terminal regulatory domain of IκB (Brown et al 1995). Even the substitution 
of a single serine can considerably inhibit the degradation of IκB, and serines cannot be 
replaced by threonine showing that they are phosphorylated by a serine-specific kinase 
(DiDonato et al 1996). Immediately following phosphorylation, IκBs undergo a second post-
translational modification of polyubiquitination. Polyubiquitination involves a cascade of 
enzymatic reactions involving E1, E2 and E3 ubiquitin ligases. The acceptor sites for 
ubiquitin on IκBα are argentines 21 and 22 which cannot be substituted with lysines because 
degradation becomes considerably retarded (DiDonato et al 1996 and Scherer et al 1995).  
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The enzymes that catalyse the ubiquitination of phosphorylated IκBs are constitutively 
active. Therefore the regulation that determines the activity of IκBs lies in the 
phosphorylation step of the two N-terminal serines. The only cases where this does not 
occur is activation of NF-κB in response to UV radiation which does not involve IκB 
phosphorylation at the N-terminal sites (Bender et al 1998) and also in anoxia which 
stimulates phosphorylation of IκBα at tyrosine 42 (Imbert et al 1996). In all other cases 
however, the control of the phosphorylation of IκBs in response to all other NF-κB activating 
stimuli lies with the IKK complex.  
 
IKK is a protein complex composed of two catalytic subunits IKKα and IKKβ (DiDonato et al 
1997) and a third regulatory polypeptide IKKγ (also known as NEMO) (Rothwarf et al 1998). 
IKKα and IKKβ have very similar primary structures with their protein kinase domains found 
at their N terminus. They also share identical activation kinetics and substrate specificities 
(Mercurio et al 1997). IKKγ/NEMO does not contain a catalytic domain however IKK 
activation certainly requires an intact IKKγ subunit for activation as shown by Yamaoka et al 
(1998) when no IKK or NF-κB activity was found in IKKγ/NEMO-deficient cells following 
treatment with cytokines such as TNF and IL-1. The C-terminal region of IKKγ is particulary 
necessary for the recruitment of upstream activators (Rothwarf et al 1998). The predominant 
form of the IKK complex comprises of an IKKα-IKKβ heterodimer associated with either a 
dimer or a trimer of IKKγ (Rothwarf et al 1998).  
 
Activation of IKK depends on phosphorylation of its IKKβ subunit, and more recently, studies 
have shown that incubating cells with TNF stimulates the phosphorylation of all three IKK 
subunits (Delhase et al 1999). Like IκBs, IKKα and IKKβ are phosphorylated exclusively at 
serines present on an activation loop (Delhase et al 1999). The phosphorylation moves the 
activation loop away from the catalytic pocket which allows its interaction with substrates 
such as IκBs (Johnson et al 1996). To summarise, IKK is activated as a result of IKKβ 
phosphorylation and IKKα phosphorylation is not essential for stimulation of IKK activity, 
therefore the IKKβ subunit is the target for upstream activators involved in proinflammatory 
signalling that are recruited to the complex via IKKγ.  
Once activated IKK complexes have phosphorylated the IκB subunits of NF-κB-IκB 
complexes (triggering their ubiquitin-dependent degredation and therefore activation of NF-
κB), the activated IKKβ subunits undergo C-terminal autophosphorylation. When at least 
nine of the C-terminal serines are phosphorylated , the enzyme reaches a low activity state, 
facilitating inactivation of IKK by phosphatises once the upstream signal has disappeared. 
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Without this method of control, prolonged IKK activation would result in prolonged NF-κB 
activation followed by increased production of inflammatory mediators. Such mediators can 
further NF-κB activation (Barnes et al 1997) which without the efficient process of rapidly 
terminating IKK and NF-κB activities, would result in damage to cells and disease. For 
example, constitutively activated IKK has been detected in Hodgkin’s disease cells 
(Krappmann et al 1999). This results in constitutive NF-κB activation which protects these 
cells from induction of apoptosis by radio- and chemotherapy (Bargou et al 1997).  
 
It is likely that elevated NF-κB and IKK activity is protecting AML cells from apoptosis and 
that this protection would continue to have an effect despite treatment. Elevated IKK activity 
may be the cause of the low levels of IκBα found in AML cells in this study, more IκBα 
phosphorylations would occur, leading to increased polyubiquitination and hence a higher 
rate of IκBα degradation in the proteasome.  
 
5.7.2 Regulation of IκBα by RelB 
RelB is a transcription activator of chemokines and TNF-α in macrophages (Weih et al 1997) 
however it has been found by Xia et al (1999) that in fibroblasts RelB plays the role of 
transcription suppressor of these genes. RelB shares many common features of the NF-κB 
family but unlike other NF-κB family members, RelB cannot form homo-dimers and only 
associates efficiently with p50 and p52 (Dobrzanski et al 1994). The RelB heterodimers have 
a much lower affinity for IκBα than other NF-κB complexes do and are less susceptible to 
inhibition by IκBα (Lernbecher et al 1994). Due to the inefficient binding of RelB to IκBα, 
RelB is allowed to enter and remain in the nucleus (Dobrzanski et al 1994). Whilst in the 
nucleus, RelB can strongly induce the expression of IκBα and therefore may indirectly inhibit 
RelA or c-Rel activities by driving the expression of IκBα (Dobrzanski et al and Ferreira et al 
1998).  
 
It is thought that RelB may exert its transcriptional suppressor function in fibroblasts by 
modulating the stability of the IκBα protein (Xia et al 1999). Because RelB is known to have 
a low affinity for IκBα, RelB may affect the stability of IκBα indirectly. It has been suggested 
by Xia et al (1999) that RelB may affect the stability of IκBα by affecting IKK activity. This 
leads to the notion of a hierarchy control of one NF-κB by another NF-κB family member 
may occur in such cells.  
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Xia et al (1999) have questioned whether RelB is differentially modified in different cells. 
Perhaps in the cells of patients with AML revert to similar mechanisms of control of IκBα as 
in fibroblast cells. AML cells have been found in this study to have lower levels of RelB and 
IκBα than in normal CD34+ healthy cells. If the fibroblast mechanism of control of IκBα was 
in place in the AML cells studied, it would make sense that IκBα expression is decreased as 
a result of decreased expression of RelB. Less RelB expression would mean less RelB 
present in the nucleus of the AML cells and therefore less induction of IκBα expression by 
RelB.  
 
5.7.3 Regulation of IκBα by C/EBPβ 
CCAAT-enhancer-binding proteins (C/EBPs) are a family of transcription factors with six 
members, including C/EBTβ. They form homo- and heterodimers and play a role in cellular 
proliferation/differentiation as well as inflammation and metabolic processes (Ramji and 
Foka 2002 and Piwien-Pilipuk et al 2002). It has been shown that C/EBPβ plays a complex 
role in NF-κB-dependent gene regulation (Ramji and Foka 2002) at the promoter level, which 
lead Cappello et al (2009) to investigate whether C/EBPβ also affects NF-κB-associated 
signalling upstream of the promoter level.  
 
Cappello et al (2009) demonstrated that the transcriptional protein C/EBPβ enhances NF-κB 
activation by elevating nuclear levels of p65. Higher cystolic levels of NF-κB inhibitor IκBα 
were found in C/EBPβ knock out cells which suggests that the higher IκBα levels in the 
absence of C/EBPβ is the reason for the attenuation of the stimulus-induced increase of p65 
in the nucleus of knock out cells. C/EBPβ is involved in the regulation of IκBα at the 
transcriptional level: the IκBα promoter contains a κB as well as a C/EBPβ binding sites 
(Chiao et al 1994 and Ito et al 1994). It has also been demonstrated that under certain 
conditions, C/EBPβ negatively affects promoters containing κB sites (Stein et al 1993), 
which would lower IκBα mRNA transcription, resulting in lower protein concentrations. This 
would in turn enable increased NF-κB signalling activity as the IκB presence is lost.  
 
Differentiating pre-monocytic cells dramatically increase their nuclear C/EBPβ levels to lower 
IκBα levels in order to increase NF-κB signalling until they become mature 
monocytes/macrophages (Pham et al 2007). It is perhaps rather likely that in the AML 
patient sample cells studied in this investigation, C/EBPβ may be aberrantly expressed at 
higher levels than in normal healthy cells. This would lead to the negative regulation of IκBα 
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and the reduction of mRNA and protein levels found within the cell, which is exactly what has 
been found to occur in the AML cells of this study.  
 
The regulation that C/EBPβ exerts on the IκBα promoter under certain conditions has also 
been reported for transcriptional repressors or activators such as RBP-I and Notch 1 (Oakley 
et al 2003) and co-activators (SRC-1, SRC-2 and SRC-3) and co-repressors (HDAC1, 
HDAC3, SMRT and NCoR) (Gao et al 2001). The promoter activity of the IκBα gene is 
determined by the combined activities of all IκBα co-activators and co-repressors (Gao et al 
2005).  
 
5.7 4 Regulation of IκBα by RelA 
Rel A is a transcription factor within the NF-κB family. RelA also has a regulatory function 
relating to the inhibitory IκBα protein. Yang et al (2003) have shown that RelA can induce 
enhanced cytoplasmic retention of IκBα, thus rendering IκBα unable to enter the nucleus to 
inhibit NF-κB-DNA binding or to transport NF-κB subunits out of the nucleus. RelA was also 
shown to cause an increase in IκBα phosphorylation which therefore lead to an increase in 
IκBα degradation. Further In vivo analysis demonstrated that the RelA-induced IκBα/RelA 
interactions are specific, saturable and phosphorylation-dependent. RelA regulation of NF-
κB-IκBα complex formation is dependent on the phosphorylation of IκBα.  
 
RelA in particular was not studied in this investigation however c-Rel was looked at and 
shares a similar function to RelA. c-Rel mRNA and protein levels appear to remain normal in 
the AML patient samples used in this study. If RelA levels are also remaining normal in AML 
patient samples, RelA may be having an influence on the decreased levels of IκBα found in 
AML patient cell samples in this study. RelA may be causing the release of NF-κB inhibition 
by the same processes as described by previous findings by Yang et al (2003). It would be 
interesting and useful to further investigate the NF-κB signalling pathway by looking in 
particular at the protein and mRNA levels of RelA and its presence within AML cells.  
 
5.8 How can IκBα be increased? 
It has become obvious from this investigation that the levels of IκBα are reduced in the AML 
cell samples studied and that this has an effect on the cell such that it leads to increased NF-
κB signalling which in turn provides cancerous cells with the ability to overcome cell death. In 
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AML cells it appears it would be beneficial to the patient if levels of IκBα were brought back 
up to normal healthy levels to allow apoptosis to occur. There are a number of factors that 
can cause an increase in the amount of active IκBα present within a cell. 
 
Vitamin D 
Vitamin D can decrease NF-κB activity by increasing levels of IκBα. In cells treated with 
vitamin D, Cohen-Lehav et al (2006) found that there were decreased levels of NF-κB p65 in 
the nucleus and increased NF-κB p65 in the cytosol. There were no changes however in the 
total p65 protein and mRNA levels, the change is that the p65 is simply being transported to 
different areas within the cell. Vitamin D addition did induce a significant increase in mRNA 
and protein levels of IκBα. These elevated levels of IκBα can be explained by vitamin D-
induced prolongation of the halflife of IκBα thus increasing the stability of the IκBα molecule, 
and also by a decrease in phosphorylation events occurring on IκBα molecules. A vitamin D-
induced increase in IκBα levels will lead to decreased nuclear translocation of NF-κB 
therefore a decrease in its activity.  
 
IL-10 and IL-13 
IL-10 and IL-13 are powerful anti-inflammatory cytokines which suppress the nuclear 
localisation of NF-κB as a result of preserved protein expression of IκBα in cells (Lentsch et 
al 1997).  
 
Glucocorticoids 
Glucocorticoids are immune-suppressive agents that inhibit NF-κB activation and mediate 
this by induction of IκBα protein synthesis (Auphan et al 1995). In monocytic and 
lymphocytic cells, IκBα mRNA and protein increases as a result of treatment with 
glucocorticoids (Brostjan et al 1996). Dexamethasone in particular induces synthesis of IκBα 
mRNA and protein in monocytic cell lines which leads to an increase in IκBα levels present 
in the cytosol of cells. This presence of IκBα prevents the release and activation of NF-κB 
signalling (Brostjan et al 1996).  
 
Cytokine IL-8  
Minekawa et al (2004) have studied Neonatal necrotizing enterocolitis (NEC) in which the 
pro-inflammatory cytokine IL-8 plays an important role in the pathophysiology of the disease. 
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Another cytokine IL-1β activates the IL-8 gene by regulating the NF-κB signalling pathways 
in intestinal cells. Human breast milk was found to suppress the IL-1β-induced activation of 
the IL-8 gene promoter by inhibiting the activation pathway of NF-κB. This induces 
production of IκBα and regulates its phosphorylation. Minekawa et al (2004) concluded that 
breastmilk can increase the basal levels of IκBα which leads to more NF-κB-IκBα 
interactions, preventing NF-κB signalling. Breastmilk was also found to directly suppress the 
phosphorylation of IκBα, preventing its degradation and promoting its stability.  
 
5.9 Areas for possible further investigation or 
improvement  
 
Several conclusions have been drawn from the data presented in Figures 1 and 2, however 
much of the data presents large amounts of error represented by the error bars shown on 
the figures. To be certain about the conclusions drawn from these results, they perhaps 
could be repeated further to reduce the error. Error was possibly caused by using different 
mRNA preparations for individual patient samples therefore this should be avoided.  
 
Western blots should also be run to investigate the levels of protein for NF-κB components 
present in the cytoplasm and in the nucleus. Detecting levels of protein by western blotting 
would further support the present protein expression data which used immunofluorescence 
to detect the presence of NF-κB proteins within the AML cells.  
 
AML cell lines were treated with anti-TNF to observe the effects of the treatment on levels of 
IκBα mRNA within the cells (Fig 5). It was observed that each cell line had a peak in IκBα 
mRNA levels at either four hours (THP-1) or eight hours (HL60 and U937) following anti-TNF 
treatment. Following this peak, IκBα mRNA levels decreased again but not to levels prior to 
anti-TNF treatment. This is an interesting observation and is worth investigating to see 
whether it holds any significance in understanding the signalling process relating to IκBα and 
NF-κB.  
 
The effect of treating AML cells with anti-TNF on mRNA levels of IκBα was investigated 
using the cell lines HL60, U937 and THP-1. As previously mentioned, these cell lines are 
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good indicators of what is likely to occur in the cells of individuals suffering from AML. To 
learn more about the effect that anti-TNF treatment is likely to have on AML cells in vivo, it 
would be necessary to do anti-TNF treatment investigations using actual AML patient cell 
samples. The same use of AML patient cell samples would also be useful when investigating 
the effects of anti-TNF on cell survival and also investigating mRNA levels of IκBα following 
treatment of anti-TNF and with the chemotherapeutic drugs daunorubicin and cytarabine.  
 
Finally, it would be useful to investigate the protein and mRNA levels of RelA and in 
particular, its distribution between the cytoplasm and nucleus of AML patient cell samples. 
RelA has not been investigated in particular in this study however cRel has been and the two 
are known to share similar functions. On the other hand, RelA in particular (and not cRel) 
has been shown to be able to enhance cytoplasmic retention of IκBα and also increase IκBα 
phosphorylation which leads to its destabilisation and degradation.  
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